Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.70 |
| ▸ | MAOA | P21397 | 3/20 | 0.50 |
| ▸ | CFTR | P13569 | 1/20 | 0.50 |
| ▸ | GOPC | Q9HD26 | 1/20 | 0.50 |
| ▸ | CES1 | P23141 | 2/20 | 0.46 |
| ▸ | BCHE | P06276 | 1/20 | 0.46 |
| ▸ | ANPEP | P15144 | 6/20 | 0.44 |
| ▸ | AHR | P35869 | 1/20 | 0.44 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.44 |
| ▸ | TDP2 | O95551 | 1/20 | 0.41 |
| ▸ | CASP3 | P42574 | 1/20 | 0.41 |
| ▸ | CASP7 | P55210 | 1/20 | 0.41 |
| ▸ | CASP9 | P55211 | 1/20 | 0.41 |
| ▸ | CASP6 | P55212 | 1/20 | 0.41 |
| ▸ | CASP8 | Q14790 | 1/20 | 0.41 |
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | DRD2 | P14416 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29366435 | 1.00 | CYP1A2 (1.00) | CYP1A2CYP2A6MAOACFTRGOPC | |
| SCHEMBL10463768 | 0.97 | CYP1A2 (0.94) | CYP1A2CYP2A6MAOACFTRGOPC | |
| Ammonia Solution, Strong SCHEMBL13736473 | 0.97 | CYP1A2 (0.94) | CYP1A2CYP2A6MAOACFTRGOPC | |
| SCHEMBL4987541 | 0.85 | CYP1A2 (0.74) | CYP1A2CYP2A6MAOACFTRGOPC | |
| SCHEMBL15777583 | 0.85 | CYP1A2 (0.74) | CYP1A2CYP2A6MAOACFTRGOPC | |
| Isothiocyanate SCHEMBL31326860 | 0.84 | CYP1A2 (0.71) | CYP1A2CYP2A6MAOACFTRGOPC | |
| SCHEMBL29411939 | 0.83 | CYP2A6 (1.00) | CYP1A2CYP2A6MAOACES1BCHE | |
| SCHEMBL10847 | 0.83 | CYP2A6 (1.00) | CYP1A2CYP2A6MAOACES1BCHE | |
| SCHEMBL11144319 | 0.81 | MAOA (0.81) | CYP1A2CYP2A6MAOACES1BCHE | |
| SCHEMBL30532246 | 0.81 | CYP1A2 (0.67) | CYP1A2CYP2A6MAOACFTRGOPC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 864 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113522294-B | Ni-based catalyst, preparation method thereof and application thereof in reductive amination | 中国科学院青岛生物能源与过程研究所 | 2023-08-29 | — | — | CN | claimed |
| CN-116239474-A | Preparation method of indacaterol intermediate 5, 6-diethyl-2, 3-dihydro-1H-indene-2-amine hydrochloride | 石家庄手性化学有限公司 | 2023-06-09 | — | — | CN | claimed |
| CN-115999537-A | Porous composite oxide encapsulated metal catalyst and preparation method and application thereof | 中国科学院青岛生物能源与过程研究所 | 2023-04-25 | — | — | CN | claimed |
| CN-111116375-B | Method for preparing primary amine by catalyzing aldehyde ketone compound through reductive amination | 中国科学院广州能源研究所 | 2023-04-07 | — | — | CN | claimed |
| CN-113522294-A | Ni-based catalyst, preparation method thereof and application thereof in reductive amination | 中国科学院青岛生物能源与过程研究所 | 2021-10-22 | — | — | CN | claimed |
| EP-3649184-A1 | SILICONE COMPOUNDS | The Procter and Gamble Company (US) | 2020-05-13 | — | — | EP | claimed |
| EP-3649183-A1 | SILICONE COMPOUNDS | The Procter and Gamble Company (US) | 2020-05-13 | — | — | EP | claimed |
| CN-111116375-A | Method for preparing primary amine by catalyzing aldehyde ketone compound through reductive amination | 中国科学院广州能源研究所 | 2020-05-08 | — | — | CN | claimed |
| US-20190010427-A1 | SILICONE COMPOUNDS | THE PROCTER & GAMBLE COMPANY | 2019-01-10 | — | — | US | claimed |
| US-20190010293-A1 | SILICONE COMPOUNDS | THE PROCTER & GAMBLE COMPANY | 2019-01-10 | — | — | US | claimed |
| WO-2019010265-A1 | SILICONE COMPOUNDS | THE PROCTER & GAMBLE COMPANY (US) | 2019-01-10 | — | — | WO | claimed |
| WO-2019010263-A1 | SILICONE COMPOUNDS | THE PROCTER & GAMBLE COMPANY (US) | 2019-01-10 | — | — | WO | claimed |
| US-20160168114-A1 | Oxone-Aceton Mediated Metal Free Preparation of Syn-Diols | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2016-06-16 | — | — | US | claimed |
| WO-2014207766-A1 | OXONE-ACETONE MEDIATED METAL FREE PREPARATION OF SYN-DIOLS | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2014-12-31 | — | — | WO | claimed |
| US-8895781-B2 | Transition metal-catalyzed C—H amination using unactivated amines | GEORGETOWN UNIVERSITY (US) | 2014-11-25 | — | — | US | claimed |
| US-20110213146-A1 | Transition Metal-Catalyzed C-H Amination Using Unactivated Amines | GEORGETOWN UNIVERSITY (US) | 2011-09-01 | — | — | US | claimed |
| WO-2010028159-A2 | TRANSITION METAL-CATALYZED C-H AMINATION USING UNACTIVATED AMINES | GEORGETOWN UNIVERSITY (US) | 2010-03-11 | — | — | WO | claimed |
| EP-0745099-A1 | REACTOR BLEND POLYPROPYLENE, PROCESS FOR THE PREPARATION THEREOF AND PROCESS FOR PREPARING METALLOCENE LIGANDS | Montell Technology Company bv (NL) | 1996-12-04 | — | — | EP | claimed |
| WO-1996020225-A2 | REACTOR BLEND POLYPROPYLENE, PROCESS FOR THE PREPARATION THEREOF AND PROCESS FOR PREPARING METALLOCENE LIGANDS | MONTELL TECHNOLOGY COMPANY B.V. (NL) | 1996-07-04 | — | — | WO | claimed |
| EP-4705281-A1 | COMPOUNDS FOR TREATING CANCER | Genesis Molecular AI, Inc. (US) | 2026-03-11 | — | — | EP | disclosed |
| US-12358887-B2 | IKAROS Zinc Finger Family degraders and uses thereof | GILEAD SCIENCES, INC. (US) | 2025-07-15 | — | — | US | disclosed |
| US-20250205204-A1 | Transcription Factor Brn2 Inhibitory Compounds for Use as Therapeutics | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2025-06-26 | — | — | US | disclosed |
| WO-2025104411-A1 | THERAPEUTIC COMPOUNDS | C4X DISCOVERY LIMITED (GB) | 2025-05-22 | — | — | WO | disclosed |
| EP-4522596-A1 | DIHYDROINDENE DERIVATIVES AS MALT1 INHIBITORS | C4X Discovery Limited (GB) | 2025-03-19 | — | — | EP | disclosed |
| US-20250066378-A1 | SPIRO-OXAZOLONES | HOFFMANN-LA ROCHE INC. (US) | 2025-02-27 | — | — | US | disclosed |
| US-12209092-B2 | Inhibitors of GLI1 as therapeutic agents | NEW YORK UNIVERSITY (US) | 2025-01-28 | — | — | US | disclosed |
| EP-4477647-A1 | CONDENSED PYRIDINES AS ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | Universal Display Corporation (US) | 2024-12-18 | — | — | EP | disclosed |
| US-12162887-B2 | Spiro-oxazolones | HOFFMANN-LA ROCHE INC. (US) | 2024-12-10 | — | — | US | disclosed |
| US-20240398772-A1 | OXASPIRO DERIVATIVE, AND PREPARATION METHOD THEREFOR AND USE THEREOF | JIANGSU NHWA PHARMACEUTICAL CO., LTD (CN) | 2024-12-05 | — | — | US | disclosed |
| EP-4464703-A2 | IKAROS ZINC FINGER FAMILY DEGRADERS AND USES THEREOF | Gilead Sciences, Inc. (US) | 2024-11-20 | — | — | EP | disclosed |
| WO-2024229121-A1 | COMPOUNDS FOR TREATING CANCER | GENESIS THERAPEUTICS, INC. (US) | 2024-11-07 | — | — | WO | disclosed |
| EP-4245756-B1 | IKAROS ZINC FINGER FAMILY DEGRADERS AND USES THEREOF | GILEAD SCIENCES INC (US) | 2024-10-09 | — | — | EP | disclosed |
| EP-4433482-A1 | SYNTHESIS OF 2'-(7,7-DIMETHYL-1'H,7H-SPIRO[FURO[3,4-B]PYRIDINE-5,4'-PIPERIDIN]-1'-YL)-1,3-DIHYDRO-4'H-SPIRO[INDENE-2,5'-[1,3]OXAZOL]-4'-ONE, AND CRYSTALLINE FORMS THEREOF | F. Hoffmann-La Roche AG (CH) | 2024-09-25 | — | — | EP | disclosed |
| US-20240309013-A1 | SYNTHESIS OF 2'-(7,7-dimethyl-1'H,7H-spiro[furo[3,4-b]pyridine-5,4'-piperidin]-1'-yl)-1,3-dihydro-4'H-spiro[indene-2,5'-[1,3]oxazol]-4'-one | HOFFMANN-LA ROCHE INC. (US) | 2024-09-19 | — | — | US | disclosed |
| CN-118324762-A | Compounds and compositions for treating CNS disorders | 布鲁奥科制药有限公司 | 2024-07-12 | — | — | CN | disclosed |
| US-12030857-B2 | Glucose uptake inhibitors | KADMON CORPORATION, LLC (US) | 2024-07-09 | — | — | US | disclosed |
| CN-118119606-A | Cyclic peroxides as prodrugs for drug selective delivery | 加利福尼亚大学董事会 | 2024-05-31 | — | — | CN | disclosed |
| EP-4375286-A1 | OXASPIRO DERIVATIVE, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Shujing Biopharma Co., Ltd (CN) | 2024-05-29 | — | — | EP | disclosed |
| WO-2024107906-A2 | IONIZABLE LIPIDS AND LIPID NANOPARTICLE COMPOSITIONS FOR THE DELIVERY OF NUCLEIC ACIDS | SEAWOLF THERAPEUTICS, INC. (US) | 2024-05-23 | — | — | WO | disclosed |
| US-20240150293-A1 | SPIROCYCLOHEXANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS ANTI-APOPTOTIC INHIBITORS | VERNALIS (R&D) LTD (GB) | 2024-05-09 | — | — | US | disclosed |
| EP-4126855-B1 | COMPOUNDS AND THEIR USE IN THE TREATMENT OF BACTERIAL INFECTIONS | HOFFMANN LA ROCHE (CH) | 2024-04-24 | — | — | EP | disclosed |
| CN-117751126-A | Oxaspiro derivative, preparation method and application thereof | 上海枢境生物科技有限公司 | 2024-03-22 | — | — | CN | disclosed |
| US-11897862-B2 | IKAROS zinc finger family degraders and uses thereof | GILEAD SCIENCES, INC. (US) | 2024-02-13 | — | — | US | disclosed |
| WO-2024030651-A1 | GPX4 INHIBITORS AND USE THEREOF | SONATA THERAPEUTICS, INC. (US) | 2024-02-08 | — | — | WO | disclosed |
| US-20230382925-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMA (US) | 2023-11-30 | — | — | US | disclosed |
| US-20230382925-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMA (US) | 2023-11-30 | — | — | US | disclosed |
| US-20230382925-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMA (US) | 2023-11-30 | — | — | US | disclosed |
| US-20230373950-A1 | IKAROS ZINC FINGER FAMILY DEGRADERS AND USES THEREOF | GILEAD SCIENCES, INC. | 2023-11-23 | — | — | US | disclosed |
| EP-4277892-A1 | SPIROCYCLOHEXANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS ANTI-APOPTOTIC INHIBITORS | Les Laboratoires Servier (FR) | 2023-11-22 | — | — | EP | disclosed |
| WO-2023218203-A1 | DIHYDROINDENE DERIVATIVES AS MALT1 INHIBITORS | C4X DISCOVERY LIMITED (GB) | 2023-11-16 | — | — | WO | disclosed |
| US-11795129-B2 | Dinuclear copper catalyst for the oxidation/oxygenation of hydrocarbons | THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEES (US) | 2023-10-24 | — | — | US | disclosed |
| CN-116940552-A | Spirocyclic hexane derivatives, pharmaceutical compositions containing them and their use as anti-apoptotic inhibitors | 法国施维雅药厂 | 2023-10-24 | — | — | CN | disclosed |
| US-20230312474-A1 | PHENOL DERIVATIVE | Sumitomo Pharma Co., Ltd. (JP) | 2023-10-05 | — | — | US | disclosed |
| US-20230295111-A1 | IKAROS ZINC FINGER FAMILY DEGRADERS AND USES THEREOF | GILEAD SCIENCES, INC. | 2023-09-21 | — | — | US | disclosed |
| EP-4245756-A1 | IKAROS ZINC FINGER FAMILY DEGRADERS AND USES THEREOF | Gilead Sciences, Inc. (US) | 2023-09-20 | — | — | EP | disclosed |
| CN-116783204-A | Modulators of cystic fibrosis transmembrane conductance regulator | 弗特克斯药品有限公司 | 2023-09-19 | — | — | CN | disclosed |
| US-20230271933-A1 | HETEROCYCLIC IMMUNOMODULATOR | BEIJING INNOCARE PHARMA TECH CO., LTD. (CN) | 2023-08-31 | — | — | US | disclosed |
| EP-3301088-B1 | CONDENSED PYRIDINES AS ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | UNIVERSAL DISPLAY CORP (US) | 2023-08-30 | — | — | EP | disclosed |
| EP-3301088-B1 | CONDENSED PYRIDINES AS ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | UNIVERSAL DISPLAY CORP (US) | 2023-08-30 | — | — | EP | disclosed |
| CN-113522294-B | Ni-based catalyst, preparation method thereof and application thereof in reductive amination | 中国科学院青岛生物能源与过程研究所 | 2023-08-29 | — | — | CN | disclosed |
| EP-4225764-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | Vertex Pharmaceuticals Incorporated (US) | 2023-08-16 | — | — | EP | disclosed |
| EP-4217412-A1 | WASTE MITIGATION METHODS AND MATERIALS | Finite Research Ltd (GB) | 2023-08-02 | — | — | EP | disclosed |
| US-20230219946-A1 | PYRIMIDIN-4(3H)-ONE HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL USE THEREOF | BEIJING INNOCARE PHARMA TECH CO., LTD. (CN) | 2023-07-13 | — | — | US | disclosed |
| US-20230192578-A1 | DINUCLEAR COPPER CATALYST FOR THE OXIDATION/OXYGENATION OF HYDROCARBONS | THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEES (US) | 2023-06-22 | — | — | US | disclosed |
| US-20230192691-A1 | HETEROCYCLIC COMPOUNDS AS BTK INHIBITORS | BEIJING INNOCARE PHARMA TECH CO LTD (CN) | 2023-06-22 | — | — | US | disclosed |
| US-20230183218-A1 | CONDENSED SUBSTITUTED HYDROPYRROLES AS ANTAGONISTS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | VANDERBILT UNIVERSITY | 2023-06-15 | — | — | US | disclosed |
| CN-116239474-A | Preparation method of indacaterol intermediate 5, 6-diethyl-2, 3-dihydro-1H-indene-2-amine hydrochloride | 石家庄手性化学有限公司 | 2023-06-09 | — | — | CN | disclosed |
| CN-116239561-A | Benzofluorene photochromic compound and application thereof | 上海甘田光学材料有限公司 | 2023-06-09 | — | — | CN | disclosed |
| US-20230174470-A1 | COMPOUND AS A UBR BOX DOMAIN LIGAND | AUTOTAC INC. (KR) | 2023-06-08 | — | — | US | disclosed |
| US-20230174548-A1 | SYMBIOTIC PRODRUGS FOR THE TREATMENT OF CANCER AND OTHER DISEASES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-06-08 | — | — | US | disclosed |
| US-11666661-B2 | Methods and compounds for targeted autophagy | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-06-06 | — | — | US | disclosed |
| US-11666661-B2 | Methods and compounds for targeted autophagy | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-06-06 | — | — | US | disclosed |
| US-20230167447-A1 | Compositions for FNIP1/FNIP2 Gene Modulation and Methods Thereof | GENETIC INTELLIGENCE INC (US) | 2023-06-01 | — | — | US | disclosed |
| US-20230167127-A1 | COMPOUNDS AND THEIR USE IN THE TREATMENT OF BACTERIAL INFECTION | HOFFMANN-LA ROCHE INC. (US) | 2023-06-01 | — | — | US | disclosed |
| WO-2023088996-A1 | SYNTHESIS OF 2'-(7,7-DIMETHYL-1'H,7H-SPIRO[FURO[3,4-B]PYRIDINE-5,4'-PIPERIDIN]-1'-YL)-1,3-DIHYDRO-4'H-SPIRO[INDENE-2,5'-[1,3]OXAZOL]-4'-ONE, AND CRYSTALLINE FORMS THEREOF | F. HOFFMANN-LA ROCHE AG (CH) | 2023-05-25 | — | — | WO | disclosed |
| WO-2023088996-A1 | SYNTHESIS OF 2'-(7,7-DIMETHYL-1'H,7H-SPIRO[FURO[3,4-B]PYRIDINE-5,4'-PIPERIDIN]-1'-YL)-1,3-DIHYDRO-4'H-SPIRO[INDENE-2,5'-[1,3]OXAZOL]-4'-ONE, AND CRYSTALLINE FORMS THEREOF | F. HOFFMANN-LA ROCHE AG (CH) | 2023-05-25 | — | — | WO | disclosed |
| US-20230150975-A1 | COMPOUNDS USED AS KINASE INHIBITORS AND APPLICATION THEREOF | TYK MEDICINES (ZHENGZHOU), INC. (CN) | 2023-05-18 | — | — | US | disclosed |
| US-20230150975-A1 | COMPOUNDS USED AS KINASE INHIBITORS AND APPLICATION THEREOF | TYK MEDICINES (ZHENGZHOU), INC. (CN) | 2023-05-18 | — | — | US | disclosed |
| US-11649251-B2 | Substituted inhibitors of menin-MLL and methods of use | KURA ONCOLOGY, INC. (US) | 2023-05-16 | — | — | US | disclosed |
| CN-115999537-A | Porous composite oxide encapsulated metal catalyst and preparation method and application thereof | 中国科学院青岛生物能源与过程研究所 | 2023-04-25 | — | — | CN | disclosed |
| US-20230116114-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CNS DISORDERS | BLUE OAK PHARMACEUTICALS, INC. | 2023-04-13 | — | — | US | disclosed |
| CN-111116375-B | Method for preparing primary amine by catalyzing aldehyde ketone compound through reductive amination | 中国科学院广州能源研究所 | 2023-04-07 | — | — | CN | disclosed |
| WO-2023049829-A2 | CYCLIC PEROXIDES AS PRODRUGS FOR SELECTIVE DELIVERY OF AGENTS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-03-30 | — | — | WO | disclosed |
| EP-3883932-B1 | INHIBITORS OF GLI1 AS THERAPEUTIC AGENTS | UNIV NEW YORK (US) | 2023-03-29 | — | — | EP | disclosed |
| EP-4139302-A1 | CONDENSED SUBSTITUTED HYDROPYRROLES AS ANTAGONISTS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | Vanderbilt University (US) | 2023-03-01 | — | — | EP | disclosed |
| EP-3246317-B1 | BTK INHIBITOR | HUBEI BIO PHARMACEUTICAL INDUSTRIAL TECH INSTITUTE INC (CN) | 2023-02-22 | — | — | EP | disclosed |
| US-11584704-B2 | Dinuclear copper catalyst for the oxidation/oxygenation of hydrocarbons | THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEES (US) | 2023-02-21 | — | — | US | disclosed |
| US-11578077-B2 | Spiro-oxazolones | HOFFMANN-LA ROCHE INC. (US) | 2023-02-14 | — | — | US | disclosed |
| WO-2023011422-A1 | OXASPIRO DERIVATIVE, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 上海枢境生物科技有限公司 | 2023-02-09 | — | — | WO | disclosed |
| WO-2023011422-A1 | OXASPIRO DERIVATIVE, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 上海枢境生物科技有限公司 | 2023-02-09 | — | — | WO | disclosed |
| CN-115353667-A | Method and material for reducing waste | 李蓁蓁 | 2022-11-18 | — | — | CN | disclosed |
| EP-4084797-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CNS DISORDERS | Blue Oak Pharmaceuticals, Inc. (US) | 2022-11-09 | — | — | EP | disclosed |
| CN-114929235-A | Compounds and compositions for treating CNS disorders | 布鲁奥科制药有限公司 | 2022-08-19 | — | — | CN | disclosed |
| CN-110891615-B | System and method for selecting and releasing fragrance | 阿甘香气及精细化学有限公司 | 2022-08-05 | — | — | CN | disclosed |
| US-20220234977-A1 | Dinuclear Copper Catalyst for the Oxidation/Oxygenation of Hydrocarbons | THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEES (US) | 2022-07-28 | — | — | US | disclosed |
| WO-2022152705-A1 | SPIROCYCLOHEXANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS ANTI-APOPTOTIC INHIBITORS | LES LABORATOIRES SERVIER (FR) | 2022-07-21 | — | — | WO | disclosed |
| WO-2022121805-A1 | FUSED RING COMPOUND AS NAV1.8 INHIBITOR AND USE THEREOF | 成都康弘药业集团股份有限公司 | 2022-06-16 | — | — | WO | disclosed |
| CN-114591293-A | Fused ring compound as Nav1.8 inhibitor and application thereof | 成都康弘药业集团股份有限公司 | 2022-06-07 | — | — | CN | disclosed |
| WO-2022076624-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2022-04-14 | — | — | WO | disclosed |
| US-11254759-B2 | Transition metal compound for olefin polymerization catalyst, and olefin polymerization catalyst including same | Hanwha Solutions Corporation (KR) | 2022-02-22 | — | — | US | disclosed |
| EP-3950676-A1 | PREPARATION METHOD FOR AMIDE COMPOUND AND APPLICATION THEREOF IN FIELD OF MEDICINE | Shanghai Synergy Pharmaceutical Sciences Co., Ltd (CN) | 2022-02-09 | — | — | EP | disclosed |
| EP-3950682-A1 | PREPARATION METHOD FOR AMIDE COMPOUNDS AND USE THEREOF IN MEDICAL FIELD | Shanghai Synergy Pharmaceutical Sciences Co., Ltd (CN) | 2022-02-09 | — | — | EP | disclosed |
| WO-2022023916-A1 | WASTE MITIGATION METHODS AND MATERIALS | LI, Zhenzhen (CN) | 2022-02-03 | — | — | WO | disclosed |
| US-20220025119-A1 | WASTE MITIGATION METHODS AND MATERIALS | LI SHENSHEN (US) | 2022-01-27 | — | — | US | disclosed |
| US-20220024941-A1 | Preparation Method for Amide Compounds and Use Thereof in Medical Field | SHANGHAI SYNERGY PHARMACEUTICAL SCIENCES CO., LTD. (CN) | 2022-01-27 | — | — | US | disclosed |
| US-20220017541-A1 | INHIBITORS OF ARGINASE | Praxis Biotech LLC | 2022-01-20 | — | — | US | disclosed |
| US-20220009935-A1 | INHIBITORS OF GLI1 AS THERAPEUTIC AGENTS | NEW YORK UNIVERSITY | 2022-01-13 | — | — | US | disclosed |
| US-11196010-B2 | Organic electroluminescent materials and devices | UNIVERSAL DISPLAY CORPORATION (US) | 2021-12-07 | — | — | US | disclosed |
| US-11196010-B2 | Organic electroluminescent materials and devices | UNIVERSAL DISPLAY CORPORATION (US) | 2021-12-07 | — | — | US | disclosed |
| US-11189804-B2 | Organic electroluminescent materials and devices | UNIVERSAL DISPLAY CORPORATION (US) | 2021-11-30 | — | — | US | disclosed |
| US-11189804-B2 | Organic electroluminescent materials and devices | UNIVERSAL DISPLAY CORPORATION (US) | 2021-11-30 | — | — | US | disclosed |
| US-11186532-B1 | Dinuclear copper catalyst for the oxidation/oxygenation of hydrocarbons | THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEES (US) | 2021-11-30 | — | — | US | disclosed |
| US-11183642-B2 | Organic electroluminescent materials and devices | UNIVERSAL DISPLAY CORPORATION (US) | 2021-11-23 | — | — | US | disclosed |
| US-11183642-B2 | Organic electroluminescent materials and devices | UNIVERSAL DISPLAY CORPORATION (US) | 2021-11-23 | — | — | US | disclosed |
| WO-2021216949-A1 | CONDENSED SUBSTITUTED HYDROPYRROLES AS ANTAGONISTS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | VANDERBILT UNIVERSITY (US) | 2021-10-28 | — | — | WO | disclosed |
| CN-113522294-A | Ni-based catalyst, preparation method thereof and application thereof in reductive amination | 中国科学院青岛生物能源与过程研究所 | 2021-10-22 | — | — | CN | disclosed |
| WO-2021190727-A1 | COMPOUNDS AND THEIR USE IN THE TREATMENT OF BACTERIAL INFECTION | F. HOFFMANN-LA ROCHE AG (CH) | 2021-09-30 | — | — | WO | disclosed |
| US-11127906-B2 | Organic electroluminescent materials and devices | UNIVERSAL DISPLAY CORPORATION (US) | 2021-09-21 | — | — | US | disclosed |
| US-11127906-B2 | Organic electroluminescent materials and devices | UNIVERSAL DISPLAY CORPORATION (US) | 2021-09-21 | — | — | US | disclosed |
| CN-113387976-A | Method for synthesizing enol silyl ether compound | 淮北师范大学 | 2021-09-14 | — | — | CN | disclosed |
| CN-113316577-A | GLi1 inhibitors as therapeutic agents | 纽约大学 | 2021-08-27 | — | — | CN | disclosed |
| US-20210253558-A1 | Inhibitors of Prolyl-tRNA-Synthetase | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2021-08-19 | — | — | US | disclosed |
| EP-3363437-B1 | AMINOINDANE COMPOUNDS AND USE THEREOF IN TREATING PAIN | ENDO PHARMACEUTICALS SOLUTIONS (US) | 2021-07-28 | — | — | EP | disclosed |
| US-10961256-B2 | PRMT5 inhibitors | CTXT PTY LTD (AU) | 2021-03-30 | — | — | US | disclosed |
| US-20210059251-A1 | PLANT GROWTH REGULATOR COMPOUNDS | SYNGENTA PARTICIPATIONS AG (CH) | 2021-03-04 | — | — | US | disclosed |
| US-20200392260-A1 | TRANSITION METAL COMPOUND FOR OLEFIN POLYMERIZATION CATALYST, AND OLEFIN POLYMERIZATION CATALYST INCLUDING SAME | Hanwha Solutions Corporation (KR) | 2020-12-17 | — | — | US | disclosed |
| EP-3426640-B1 | PRMT5 INHIBITORS | CTXT PTY LTD (AU) | 2020-11-18 | — | — | EP | disclosed |
| WO-2020192652-A1 | PREPARATION METHOD FOR AMIDE COMPOUNDS AND USE THEREOF IN MEDICAL FIELD | 上海华汇拓医药科技有限公司 | 2020-10-01 | — | — | WO | disclosed |
| WO-2020192650-A1 | PREPARATION METHOD FOR AMIDE COMPOUND AND APPLICATION THEREOF IN FIELD OF MEDICINE | 上海华汇拓医药科技有限公司 | 2020-10-01 | — | — | WO | disclosed |
| US-10774060-B2 | Oxone-aceton mediated metal free preparation of syn-diols | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2020-09-15 | — | — | US | disclosed |
| EP-3686204-A1 | THIENODIAZEPINE DERIVATIVES AND APPLICATION THEREOF | CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. (CN) | 2020-07-29 | — | — | EP | disclosed |
| US-10662174-B2 | BTK inhibitor | HUBEI BIO-PHARMACEUTICAL INDUSTRIAL TECHNOLOGICAL INSTITUTE, INC. (CN) | 2020-05-26 | — | — | US | disclosed |
| EP-3649183-A1 | SILICONE COMPOUNDS | The Procter and Gamble Company (US) | 2020-05-13 | — | — | EP | disclosed |
| EP-3649184-A1 | SILICONE COMPOUNDS | The Procter and Gamble Company (US) | 2020-05-13 | — | — | EP | disclosed |
| CN-111116375-A | Method for preparing primary amine by catalyzing aldehyde ketone compound through reductive amination | 中国科学院广州能源研究所 | 2020-05-08 | — | — | CN | disclosed |
| US-20200062874-A1 | METALLOCENE COMPLEX WITH A HETEROATOM-CONTAINING PI-LIGAND AND PREPARATION METHOD THEREFOR, CATALYST SYSTEM CONTAINING THE SAME AND USE THEREOF | PETROCHINA COMPANY LIMITED (CN) | 2020-02-27 | — | — | US | disclosed |
| US-20200039997-A1 | SPIRO-OXAZOLONES | HOFFMANN-LA ROCHE INC. (US) | 2020-02-06 | — | — | US | disclosed |
| US-10479796-B2 | Spiro-oxazolones | HOFFMAN-LA ROCHE INC. (US) | 2019-11-19 | — | — | US | disclosed |
| WO-2019216541-A1 | TRANSITION METAL COMPOUND FOR OLEFIN POLYMERIZATION CATALYST, AND OLEFIN POLYMERIZATION CATALYST INCLUDING SAME | 한화케미칼 주식회사 (KR) | 2019-11-14 | — | — | WO | disclosed |
| EP-3564240-A1 | PIPERIDINE INTERMEDIATES | Purdue Pharma L.P. (US) | 2019-11-06 | — | — | EP | disclosed |
| CN-110372550-A | Aryl ether and application thereof | 佩洛通治疗公司 | 2019-10-25 | — | — | CN | disclosed |
| US-20190290778-A1 | METHODS AND COMPOUNDS FOR TARGETED AUTOPHAGY | FRONTIER MEDICINES CORPORATION | 2019-09-26 | — | — | US | disclosed |
| WO-2019175025-A1 | PLANT GROWTH REGULATOR COMPOUNDS | SYNGENTA PARTICIPATIONS AG (CH) | 2019-09-19 | — | — | WO | disclosed |
| US-20190237683-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | UNIVERSAL DISPLAY CORPORATION (US) | 2019-08-01 | — | — | US | disclosed |
| US-20190237683-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | UNIVERSAL DISPLAY CORPORATION (US) | 2019-08-01 | — | — | US | disclosed |
| CN-105530923-B | Aryl ethers and their use | 佩洛通治疗公司 | 2019-07-23 | — | — | CN | disclosed |
| EP-3209746-B1 | ORGANIC ELECTROLUMINESCENT DEVICE | MERCK PATENT GMBH (DE) | 2019-05-08 | — | — | EP | disclosed |
| US-20190010427-A1 | SILICONE COMPOUNDS | THE PROCTER & GAMBLE COMPANY | 2019-01-10 | — | — | US | disclosed |
| US-20190010293-A1 | SILICONE COMPOUNDS | THE PROCTER & GAMBLE COMPANY | 2019-01-10 | — | — | US | disclosed |
| WO-2019010265-A1 | SILICONE COMPOUNDS | THE PROCTER & GAMBLE COMPANY (US) | 2019-01-10 | — | — | WO | disclosed |
| WO-2019010263-A1 | SILICONE COMPOUNDS | THE PROCTER & GAMBLE COMPANY (US) | 2019-01-10 | — | — | WO | disclosed |
| US-20180240988-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | UNIVERSAL DISPLAY CORPORATION (US) | 2018-08-23 | — | — | US | disclosed |
| US-20180194739-A1 | METHODS TO TREAT LYMPHOPLASMACYTIC LYMPHOMA | DANA-FARBER CANCER INSTITUTE, INC. | 2018-07-12 | — | — | US | disclosed |
| US-20180186783-A1 | INHIBITORS OF PROTEIN KINASES | ALEXION PHARMACEUTICALS, INC. | 2018-07-05 | — | — | US | disclosed |
| US-20180186780-A1 | METHODS TO TREAT LYMPHOPLASMACYTIC LYMPHOMA | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2018-07-05 | — | — | US | disclosed |
| US-10004674-B2 | Substituted p-phenylenediamines as new oxidation dye precursor products of the developer type | HENKEL AG & CO. KGAA (DE) | 2018-06-26 | — | — | US | disclosed |
| US-20180162862-A1 | INHIBITORS OF BACTERIAL GLYCOSYL TRANSFERASES | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2018-06-14 | — | — | US | disclosed |
| US-20180162862-A1 | INHIBITORS OF BACTERIAL GLYCOSYL TRANSFERASES | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2018-06-14 | — | — | US | disclosed |
| US-20180155320-A1 | 2-OXO-1,2-DIHYDROPYRIDINE-3-CARBOXAMIDE COMPOUNDS AND THEIR USE AS INHIBITORS OF PDK1 | INTERNATIONAL SOCIETY FOR DRUG DEVELOPMENT S.R.L. (IT) | 2018-06-07 | — | — | US | disclosed |
| US-20180105531-A1 | METHODS AND COMPOSITIONS FOR INHIBITING THE INTERACTION OF MENIN WITH MLL PROTEINS | WELLSPRING BIOSCIENCES LLC | 2018-04-19 | — | — | US | disclosed |
| EP-3303338-A1 | INHIBITORS OF BACTERIAL GLYCOSYL TRANSFERASES | President and Fellows of Harvard College (US) | 2018-04-11 | — | — | EP | disclosed |
| US-20180097187-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | UNIVERSAL DISPLAY CORPORATION (US) | 2018-04-05 | — | — | US | disclosed |
| US-20180097187-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | UNIVERSAL DISPLAY CORPORATION (US) | 2018-04-05 | — | — | US | disclosed |
| US-20180097187-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | UNIVERSAL DISPLAY CORPORATION (US) | 2018-04-05 | — | — | US | disclosed |
| US-20180097179-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | UNIVERSAL DISPLAY CORPORATION (US) | 2018-04-05 | — | — | US | disclosed |
| US-20180097179-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | UNIVERSAL DISPLAY CORPORATION (US) | 2018-04-05 | — | — | US | disclosed |
| US-20180097179-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | UNIVERSAL DISPLAY CORPORATION (US) | 2018-04-05 | — | — | US | disclosed |
| EP-3301088-A1 | CONDENSED PYRIDINES AS ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | Universal Display Corporation (US) | 2018-04-04 | — | — | EP | disclosed |
| US-9932338-B2 | Compounds having muscarinic receptor antagonist and BETA2 adrenergic receptor agonist activity | CHIESI FARMACEUTICI S.P.A. (IT) | 2018-04-03 | — | — | US | disclosed |
| EP-2675787-B1 | AMINOINDANE COMPOUNDS AND USE THEREOF IN TREATING PAIN | ENDO PHARMACEUTICALS INC (US) | 2018-03-28 | — | — | EP | disclosed |
| US-20180079843-A1 | METALLOCENE COMPLEX WITH A HETEROATOM-CONTAINING PI-LIGAND AND PREPARATION METHOD THEREFOR, CATALYST SYSTEM CONTAINING THE SAME AND USE THEREOF | PETROCHINA COMPANY LIMITED (CN) | 2018-03-22 | — | — | US | disclosed |
| US-9908872-B2 | Methods to treat lymphoplasmacytic lymphoma | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2018-03-06 | — | — | US | disclosed |
| US-9868729-B2 | Inhibitors of protein kinases | PORTOLA PHARMACEUTICALS, INC. (US) | 2018-01-16 | — | — | US | disclosed |
| EP-2496559-B1 | ARYL- AND HETEROARYLCARBONYL DERIVATIVES OF HEXAHYDROINDENOPYRIDINE AND OCTAHYDROBENZOQUINOLINE AND THEIR USE AS HSD 1 INHIBITORS | VITAE PHARMACEUTICALS INC (US) | 2018-01-10 | — | — | EP | disclosed |
| US-9856223-B2 | Methods to treat lymphoplasmacytic lymphoma | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2018-01-02 | — | — | US | disclosed |
| US-20170368028-A1 | N-BENZOATE GROUP SUBSTITUTED BENZOPYRROLINE-2-ONE DERIVATIVE AND USE THEREOF | Beijing Hanmi Pharmaceutical Co., Ltd. (CN) | 2017-12-28 | — | — | US | disclosed |
| EP-2344158-B1 | USE OF ISOQC INHIBITORS | PROBIODRUG AG (DE) | 2017-12-27 | — | — | EP | disclosed |
| US-20170358760-A1 | ORGANIC ELECTROLUMINESCENT DEVICE | MERCK PATENT GMBH (DE) | 2017-12-14 | — | — | US | disclosed |
| US-20170348426-A1 | COMPOSITION COMPRISING A POLYMERIC REAGENT | NEKTAR THERAPEUTICS | 2017-12-07 | — | — | US | disclosed |
| EP-3083633-B1 | SPIRO-OXAZOLONES | HOFFMANN LA ROCHE (CH) | 2017-11-29 | — | — | EP | disclosed |
| EP-3246317-A1 | BTK INHIBITOR | Hubei Bio-Pharmaceutical Industrial Technological Institute Inc. (CN) | 2017-11-22 | — | — | EP | disclosed |
| US-9822092-B2 | ArylSulfonamide-based matrix metalloprotease inhibitors | NOVARTIS AG (CH) | 2017-11-21 | — | — | US | disclosed |
| US-9822092-B2 | ArylSulfonamide-based matrix metalloprotease inhibitors | NOVARTIS AG (CH) | 2017-11-21 | — | — | US | disclosed |
| US-20170313683-A1 | BTK INHIBITOR | HUBEI BIO-PHARMACEUTICAL INDUSTRIAL TECHNOLOGICAL INSTITUTE, INC. (CN) | 2017-11-02 | — | — | US | disclosed |
| US-20170313683-A1 | BTK INHIBITOR | HUBEI BIO-PHARMACEUTICAL INDUSTRIAL TECHNOLOGICAL INSTITUTE, INC. (CN) | 2017-11-02 | — | — | US | disclosed |
| US-9775911-B2 | Composition comprising a polymeric reagent | NEKTAR THERAPEUTICS (US) | 2017-10-03 | — | — | US | disclosed |
| US-9776963-B2 | Small molecule CD4 mimetics and uses thereof | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2017-10-03 | — | — | US | disclosed |
| US-9765063-B2 | Amido compounds as RORγt modulators and uses thereof | NEW YORK UNIVERSITY (US) | 2017-09-19 | — | — | US | disclosed |
| WO-2017153518-A1 | PRMT5 INHIBITORS | CTXT PTY LIMITED (AU) | 2017-09-14 | — | — | WO | disclosed |
| US-9745267-B2 | Compounds as modulators of RORC | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2017-08-29 | — | — | US | disclosed |
| US-20170240537-A1 | PRMT5 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2017-08-24 | — | — | US | disclosed |
| CN-106999972-A | System and method for discharging fragrance | 阿甘芳香和精细化工有限公司 | 2017-08-01 | — | — | CN | disclosed |
| US-20170165166-A1 | SUBSTITUTED P-PHENYLENEDIAMINES AS NEW OXIDATION DYE PRECURSOR PRODUCTS OF THE DEVELOPER TYPE | HENKEL AG & CO. KGAA (DE) | 2017-06-15 | — | — | US | disclosed |
| US-20170158702-A1 | MULTIVALENT RAS BINDING COMPOUNDS | KYRAS THERAPEUTICS, INC. | 2017-06-08 | — | — | US | disclosed |
| US-20170158694-A1 | COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY | CHIESI FARMACEUTICI S.P.A. (IT) | 2017-06-08 | — | — | US | disclosed |
| US-9669399-B2 | Phosphine ligands for catalytic reactions | ABBVIE INC. (US) | 2017-06-06 | — | — | US | disclosed |
| US-20170152258-A9 | Substituted Pyridopyrazines as Syk Inhibitors | HUTCHISON MEDIPHARMA LIMITED (CN) | 2017-06-01 | — | — | US | disclosed |
| US-9663470-B2 | Aryl- and heteroarylcarbonyl derivatives of hexahydroindenopyridine and octahydrobenzoquinoline | VITAE PHARMACEUTICALS, INC. (US) | 2017-05-30 | — | — | US | disclosed |
| US-9663470-B2 | Aryl- and heteroarylcarbonyl derivatives of hexahydroindenopyridine and octahydrobenzoquinoline | VITAE PHARMACEUTICALS, INC. (US) | 2017-05-30 | — | — | US | disclosed |
| US-9663470-B2 | Aryl- and heteroarylcarbonyl derivatives of hexahydroindenopyridine and octahydrobenzoquinoline | VITAE PHARMACEUTICALS, INC. (US) | 2017-05-30 | — | — | US | disclosed |
| US-9630958-B2 | Triazine compounds | SPHAERA PHARMA PTE. LTD. (SG) | 2017-04-25 | — | — | US | disclosed |
| US-9630935-B2 | Compositions for the treatment of hypertension and/or fibrosis | VECTUS BIOSYSTEMS LIMITED (AU) | 2017-04-25 | — | — | US | disclosed |
| WO-2017066705-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF USE AGAINST STRESS GRANULES | AQUINNAH PHARMACEUTICALS, INC. (US) | 2017-04-20 | — | — | WO | disclosed |
| EP-2846801-B1 | PYRIDINE CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (US) | 2017-04-05 | — | — | EP | disclosed |
| US-9611257-B2 | PRMT5 inhibitors and uses thereof | Epizyme, Inc. (US) | 2017-04-04 | — | — | US | disclosed |
| US-20170088541-A1 | PRMT5 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2017-03-30 | — | — | US | disclosed |
| US-9567308-B1 | Process for the synthesis of chlorzoxazone | PROCOS S.P.A. (IT) | 2017-02-14 | — | — | US | disclosed |
| US-9566577-B1 | Catalytic hydrogenation using complexes of base metals with tridentate ligands | LOS ALAMOS NATIONAL SECURITY, LLC (US) | 2017-02-14 | — | — | US | disclosed |
| US-9566577-B1 | Catalytic hydrogenation using complexes of base metals with tridentate ligands | LOS ALAMOS NATIONAL SECURITY, LLC (US) | 2017-02-14 | — | — | US | disclosed |
| US-20170022172-A1 | PROCESS FOR THE SYNTHESIS OF CHLORZOXAZONE | PROCOS S.P.A. (IT) | 2017-01-26 | — | — | US | disclosed |
| US-9550788-B2 | Substituted aminoindanes and analogs thereof, and the pharmaceutical use thereof | SANOFI (FR) | 2017-01-24 | — | — | US | disclosed |
| US-20170008901-A1 | SPIRO-OXAZOLONES | HOFFMANN-LA ROCHE INC. (US) | 2017-01-12 | — | — | US | disclosed |
| US-20170008901-A1 | SPIRO-OXAZOLONES | HOFFMANN-LA ROCHE INC. (US) | 2017-01-12 | — | — | US | disclosed |
| US-20170002016-A1 | AZASPIRO DERIVATIVES AS TRPM8 ANTAGONISTS | RAQUALIA PHARMA INC. (JP) | 2017-01-05 | — | — | US | disclosed |
| US-9527840-B2 | Substituted-quinoxaline-type piperidine compounds and the uses thereof | PURDUE PHARMA L.P. (US) | 2016-12-27 | — | — | US | disclosed |
| US-9527840-B2 | Substituted-quinoxaline-type piperidine compounds and the uses thereof | PURDUE PHARMA L.P. (US) | 2016-12-27 | — | — | US | disclosed |
| EP-3101018-A1 | SUBSTITUTED-QUINOXALINE-TYPE-PIPERIDINE COMPOUNDS AND THE USES THEREOF | Purdue Pharma L.P. (US) | 2016-12-07 | — | — | EP | disclosed |
| WO-2016191658-A1 | INHIBITORS OF BACTERIAL GLYCOSYL TRANSFERASES | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2016-12-01 | — | — | WO | disclosed |
| US-20160324973-A1 | COMPOSITION COMPRISING A POLYMERIC REAGENT | NEKTAR THERAPEUTICS | 2016-11-10 | — | — | US | disclosed |
| US-20160318878-A1 | METHODS TO TREAT LYMPHOPLASMACYTIC LYMPHOMA | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2016-11-03 | — | — | US | disclosed |
| US-9481670-B2 | Triazine compounds | SPHAERA PHARMA PTE. LTD. (SG) | 2016-11-01 | — | — | US | disclosed |
| US-20160311807-A1 | METHODS TO TREAT LYMPHOPLASMACYTIC LYMPHOMA | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2016-10-27 | — | — | US | disclosed |
| EP-3083633-A1 | SPIRO-OXAZOLONES | F.HOFFMANN-LA ROCHE AG (CH) | 2016-10-26 | — | — | EP | disclosed |
| US-20160280671-A1 | COMPOSITIONS FOR THE TREATMENT OF HYPERTENSION AND/OR FIBROSIS | VECTUS BIOSYSTEMS LIMITED (AU) | 2016-09-29 | — | — | US | disclosed |
| EP-2342178-B1 | SUBSTITUTED AMINOINDANES AND ANALOGS THEREOF, AND THE PHARMACEUTICAL USE THEREOF | SANOFI SA (FR) | 2016-09-28 | — | — | EP | disclosed |
| US-20160272590-A1 | ARYL- AND HETEROARYLCARBONYL DERIVATIVES OF HEXAHYDROINDENOPYRIDINE AND OCTAHYDROBENZOQUINOLINE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-09-22 | — | — | US | disclosed |
| US-20160272590-A1 | ARYL- AND HETEROARYLCARBONYL DERIVATIVES OF HEXAHYDROINDENOPYRIDINE AND OCTAHYDROBENZOQUINOLINE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-09-22 | — | — | US | disclosed |
| US-20160272590-A1 | ARYL- AND HETEROARYLCARBONYL DERIVATIVES OF HEXAHYDROINDENOPYRIDINE AND OCTAHYDROBENZOQUINOLINE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-09-22 | — | — | US | disclosed |
| US-20160263566-A1 | PHOSPHINE LIGANDS FOR CATALYTIC REACTIONS | ABBVIE INC. | 2016-09-15 | — | — | US | disclosed |
| US-9434666-B2 | Catalytic hydrogenation using complexes of base metals with tridentate ligands | LOS ALAMOS NATIONAL SECURITY, LLC (US) | 2016-09-06 | — | — | US | disclosed |
| US-9434666-B2 | Catalytic hydrogenation using complexes of base metals with tridentate ligands | LOS ALAMOS NATIONAL SECURITY, LLC (US) | 2016-09-06 | — | — | US | disclosed |
| US-20160251310-A1 | COMPOUNDS AS MODULATORS OF RORC | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-09-01 | — | — | US | disclosed |
| US-20160244460-A1 | ANTIVIRAL COMPOUNDS | Janssen Pharmaceuticals, Inc. | 2016-08-25 | — | — | US | disclosed |
| US-9416080-B2 | Catalytic C—H bond activation | GEORGETOWN UNIVERSITY (US) | 2016-08-16 | — | — | US | disclosed |
| US-9381508-B2 | Phosphine ligands for catalytic reactions | ABBVIE INC. (US) | 2016-07-05 | — | — | US | disclosed |
| US-9381254-B2 | Methods for preparing polymeric reagents | NEKTAR THERAPEUTICS (US) | 2016-07-05 | — | — | US | disclosed |
| EP-2433937-B1 | Substituted-quinoxaline-type-piperidine compounds and the uses thereof | PURDUE PHARMA LP (US) | 2016-06-29 | — | — | EP | disclosed |
| US-9375423-B2 | Use of aminoindane compounds in treating overactive bladder and interstitial cystitis | ASANA BIOSCIENCES, LLC (US) | 2016-06-28 | — | — | US | disclosed |
| US-9375423-B2 | Use of aminoindane compounds in treating overactive bladder and interstitial cystitis | ASANA BIOSCIENCES, LLC (US) | 2016-06-28 | — | — | US | disclosed |
| US-20160168114-A1 | Oxone-Aceton Mediated Metal Free Preparation of Syn-Diols | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2016-06-16 | — | — | US | disclosed |
| US-20160168114-A1 | Oxone-Aceton Mediated Metal Free Preparation of Syn-Diols | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2016-06-16 | — | — | US | disclosed |
| US-20160168114-A1 | Oxone-Aceton Mediated Metal Free Preparation of Syn-Diols | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2016-06-16 | — | — | US | disclosed |
| US-9365555-B2 | PRMT5 inhibitors and uses thereof | Epizyme, Inc. | 2016-06-14 | — | — | US | disclosed |
| US-20160159785-A1 | SUBSTITUTED-QUINOXALINE-TYPE PIPERIDINE COMPOUNDS AND THE USES THEREOF | PURDUE PHARMA L.P. | 2016-06-09 | — | — | US | disclosed |
| US-20160159785-A1 | SUBSTITUTED-QUINOXALINE-TYPE PIPERIDINE COMPOUNDS AND THE USES THEREOF | PURDUE PHARMA L.P. | 2016-06-09 | — | — | US | disclosed |
| EP-2344157-B1 | NOVEL INHIBITORS | PROBIODRUG AG (DE) | 2016-05-25 | — | — | EP | disclosed |
| US-9328072-B2 | Aryl-and heteroarylcarbonyl derivatives of hexahydroindenopyridine and octahydrobenzoquinoline | VITAE PHARMACEUTICALS, INC. (US) | 2016-05-03 | — | — | US | disclosed |
| US-9328072-B2 | Aryl-and heteroarylcarbonyl derivatives of hexahydroindenopyridine and octahydrobenzoquinoline | VITAE PHARMACEUTICALS, INC. (US) | 2016-05-03 | — | — | US | disclosed |
| US-9328072-B2 | Aryl-and heteroarylcarbonyl derivatives of hexahydroindenopyridine and octahydrobenzoquinoline | VITAE PHARMACEUTICALS, INC. (US) | 2016-05-03 | — | — | US | disclosed |
| US-9303027-B2 | Kappa opioid receptor agonists | DR. REDDY'S LABORATORIES LTD. (IN) | 2016-04-05 | — | — | US | disclosed |
| US-9278967-B2 | Substituted-quinoxaline-type piperidine compounds and the uses thereof | PURDUE PHARMA L.P. (US) | 2016-03-08 | — | — | US | disclosed |
| US-9278967-B2 | Substituted-quinoxaline-type piperidine compounds and the uses thereof | PURDUE PHARMA L.P. (US) | 2016-03-08 | — | — | US | disclosed |
| US-9266913-B2 | Phosphine ligands for catalytic reactions | ABBVIE INC. (US) | 2016-02-23 | — | — | US | disclosed |
| US-20160022830-A1 | METHODS FOR PREPARING POLYMERIC REAGENTS | NEKTAR THERAPEUTICS | 2016-01-28 | — | — | US | disclosed |
| US-9238026-B2 | Inhibitors of viral replication, their process of preparation and their therapeutical uses | LABORATOIRE BIODIM (FR) | 2016-01-19 | — | — | US | disclosed |
| US-20160002221-A1 | Substituted Pyridopyrazines as Syk Inhibitors | HUTCHISON MEDIPHARMA LTD (CN) | 2016-01-07 | — | — | US | disclosed |
| EP-2686324-B1 | PIPERIDINE CARBOXAMIDE SPIROHYDANTOIN CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (US) | 2016-01-06 | — | — | EP | disclosed |
| US-9227973-B2 | Pyridine CGRP receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2016-01-05 | — | — | US | disclosed |
| US-9227973-B2 | Pyridine CGRP receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2016-01-05 | — | — | US | disclosed |
| US-9227944-B2 | Dopamine D3 receptor ligands and preparation and medical uses of the same | INSTITUTE OF PHARMACOLOGY AND TOXICOLOGY ACADEMY OF MILITARY SCIENCE P.L.A. CHINA (CN) | 2016-01-05 | — | — | US | disclosed |
| US-20150360215-A1 | PHOSPHINE LIGANDS FOR CATALYTIC REACTIONS | ABBVIE INC. | 2015-12-17 | — | — | US | disclosed |
| US-20150344457-A1 | METHODS OF INHIBITING PRMT5 | Epizyme, Inc. (US) | 2015-12-03 | — | — | US | disclosed |
| US-20150344463-A1 | PRMT5 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2015-12-03 | — | — | US | disclosed |
| US-9200021-B2 | Phosphine ligands for catalytic reactions | ABBVIE INC. (US) | 2015-12-01 | — | — | US | disclosed |
| US-20150336862-A1 | CATALYTIC HYDROGENATION USING COMPLEXES OF BASE METALS WITH TRIDENTATE LIGANDS | LOS ALAMOS NATIONAL SECURITY, LLC (US) | 2015-11-26 | — | — | US | disclosed |
| US-20150336862-A1 | CATALYTIC HYDROGENATION USING COMPLEXES OF BASE METALS WITH TRIDENTATE LIGANDS | LOS ALAMOS NATIONAL SECURITY, LLC (US) | 2015-11-26 | — | — | US | disclosed |
| US-20150321982-A1 | Catalytic C-H Bond Activation | NATIONAL SCIENCE FOUNDATION | 2015-11-12 | — | — | US | disclosed |
| US-20150290182-A1 | USE OF AMINOINDANE COMPOUNDS IN TREATING OVERACTIVE BLADDER AND INTERSTITIAL CYSTITIS | ASANA BIOSCIENCES, LLC (US) | 2015-10-15 | — | — | US | disclosed |
| US-20150290182-A1 | USE OF AMINOINDANE COMPOUNDS IN TREATING OVERACTIVE BLADDER AND INTERSTITIAL CYSTITIS | ASANA BIOSCIENCES, LLC (US) | 2015-10-15 | — | — | US | disclosed |
| EP-2137179-B1 | PYRIDAZINONE DERIVATIVES USEFUL AS GLUCAN SYNTHASE INHIBITORS | MERCK SHARP & DOHME (US) | 2015-09-02 | — | — | EP | disclosed |
| US-9120769-B2 | Aryl-and heteroarylcarbonyl derivatives of hexahydroindenopyridine and octahydrobenzoquinoline | BOEHRINGER-INGELHEIM INTERNATIONAL GMBH (DE) | 2015-09-01 | — | — | US | disclosed |
| US-9120769-B2 | Aryl-and heteroarylcarbonyl derivatives of hexahydroindenopyridine and octahydrobenzoquinoline | BOEHRINGER-INGELHEIM INTERNATIONAL GMBH (DE) | 2015-09-01 | — | — | US | disclosed |
| US-9120769-B2 | Aryl-and heteroarylcarbonyl derivatives of hexahydroindenopyridine and octahydrobenzoquinoline | BOEHRINGER-INGELHEIM INTERNATIONAL GMBH (DE) | 2015-09-01 | — | — | US | disclosed |
| US-9090740-B2 | Methods for preparing polymeric reagents | NEKTAR THERAPEUTICS (US) | 2015-07-28 | — | — | US | disclosed |
| US-20150197515-A1 | NOVEL TRIAZINE COMPOUNDS | SPHAERA PHARMA PTE. LTD. (SG) | 2015-07-16 | — | — | US | disclosed |
| WO-2015091411-A1 | SPIRO-OXAZOLONES | F. HOFFMANN-LA ROCHE AG (CH) | 2015-06-25 | — | — | WO | disclosed |
| US-20150152126-A1 | PHOSPHINE LIGANDS FOR CATALYTIC REACTIONS | ABBVIE INC. | 2015-06-04 | — | — | US | disclosed |
| US-9044482-B2 | Use of aminoindane compounds in treating overactive bladder and interstitial cystitis | ASANA BIOSCIENCES, LLC (US) | 2015-06-02 | — | — | US | disclosed |
| US-9044482-B2 | Use of aminoindane compounds in treating overactive bladder and interstitial cystitis | ASANA BIOSCIENCES, LLC (US) | 2015-06-02 | — | — | US | disclosed |
| US-20150141665-A1 | METHODS FOR PREPARING POLYMERIC REAGENTS | NEKTAR THERAPEUTICS (US) | 2015-05-21 | — | — | US | disclosed |
| US-20150141643-A1 | SUBSTITUTED-QUINOXALINE-TYPE PIPERIDINE COMPOUNDS AND THE USES THEREOF | PURDUE PHARMA L.P. | 2015-05-21 | — | — | US | disclosed |
| US-20150141643-A1 | SUBSTITUTED-QUINOXALINE-TYPE PIPERIDINE COMPOUNDS AND THE USES THEREOF | PURDUE PHARMA L.P. | 2015-05-21 | — | — | US | disclosed |
| US-9023848-B2 | Small-molecules as therapeutics | BIONOMICS LIMITED (AU) | 2015-05-05 | — | — | US | disclosed |
| US-20150099771-A1 | PYRIDINE CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2015-04-09 | — | — | US | disclosed |
| US-20150099771-A1 | PYRIDINE CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2015-04-09 | — | — | US | disclosed |
| US-20150094298-A1 | INHIBITORS OF PROTEIN KINASES | PORTOLA PHARMACEUTICALS, INC. | 2015-04-02 | — | — | US | disclosed |
| US-20150087641-A1 | HETEROCYCLIC CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. | 2015-03-26 | — | — | US | disclosed |
| US-20150087641-A1 | HETEROCYCLIC CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. | 2015-03-26 | — | — | US | disclosed |
| US-8986938-B2 | Microbial activity improvement agent, microbial activity improvement method, and biological waste treatment method | SUMITOMO HEAVY INDUSTRIES, LTD. (JP) | 2015-03-24 | — | — | US | disclosed |
| US-8987314-B2 | Amide, urea or sulfone amide linked benzothiazole inhibitors of endothelial lipase | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-03-24 | — | — | US | disclosed |
| US-8975443-B2 | Phosphine ligands for catalytic reactions | ABBVIE INC. (US) | 2015-03-10 | — | — | US | disclosed |
| US-8975439-B2 | Arylsulfonamide based matrix metalloprotease inhibitors | NOVARTIS AG (CH) | 2015-03-10 | — | — | US | disclosed |
| US-8975439-B2 | Arylsulfonamide based matrix metalloprotease inhibitors | NOVARTIS AG (CH) | 2015-03-10 | — | — | US | disclosed |
| US-20150065490-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2015-03-05 | — | — | US | disclosed |
| US-20150057278-A1 | AMIDO COMPOUNDS AS RORyT MODULATORS AND USES THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-02-26 | — | — | US | disclosed |
| US-8962860-B2 | Inhibitors of glutaminyl cyclase | PROBIODRUG AG (DE) | 2015-02-24 | — | — | US | disclosed |
| US-20150045398-A1 | ArylSulfonamide-Based Matrix Metalloprotease Inhibitors | NOVARTIS AG (CH) | 2015-02-12 | — | — | US | disclosed |
| US-20150045398-A1 | ArylSulfonamide-Based Matrix Metalloprotease Inhibitors | NOVARTIS AG (CH) | 2015-02-12 | — | — | US | disclosed |
| EP-2500345-B1 | 8-AZABICYCLO[3.2.1]OCTANE-8-CARBOXAMIDE DERIVATIVE | SUMITOMO DAINIPPON PHARMA CO LTD (JP) | 2015-01-28 | — | — | EP | disclosed |
| US-8937070-B2 | Inhibitors of protein kinases | PORTOLA PHARMACEUTICALS, INC. (US) | 2015-01-20 | — | — | US | disclosed |
| EP-2086958-B1 | SUBSTITUTED-QUINOXALINE-TYPE-PIPERIDINE COMPOUNDS AND THE USES THEREOF | PURDUE PHARMA LP (US) | 2015-01-14 | — | — | EP | disclosed |
| US-8933229-B2 | 8-azabicyclo[3.2.1]octane-8-carboxamide derivative | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2015-01-13 | — | — | US | disclosed |
| US-8933229-B2 | 8-azabicyclo[3.2.1]octane-8-carboxamide derivative | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2015-01-13 | — | — | US | disclosed |
| US-8927548-B2 | Triazole compounds that modulate HSP90 activity | SYNTA PHARMACEUTICALS CORP. (US) | 2015-01-06 | — | — | US | disclosed |
| WO-2014207766-A1 | OXONE-ACETONE MEDIATED METAL FREE PREPARATION OF SYN-DIOLS | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2014-12-31 | — | — | WO | disclosed |
| WO-2014207766-A1 | OXONE-ACETONE MEDIATED METAL FREE PREPARATION OF SYN-DIOLS | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2014-12-31 | — | — | WO | disclosed |
| US-8921359-B2 | Inhibitors of beta-secretase | VITAE PHARMACEUTICALS, INC. (US) | 2014-12-30 | — | — | US | disclosed |
| US-8921359-B2 | Inhibitors of beta-secretase | VITAE PHARMACEUTICALS, INC. (US) | 2014-12-30 | — | — | US | disclosed |
| US-20140371446-A1 | PHOSPHINE LIGANDS FOR CATALYTIC REACTIONS | ABBVIE INC. (US) | 2014-12-18 | — | — | US | disclosed |
| US-8911718-B2 | Methods for preparing polymeric reagents | NEKTAR THERAPEUTICS (US) | 2014-12-16 | — | — | US | disclosed |
| US-8905235-B2 | Polymeric reagents comprising a terminal vinylic group and conjugates formed therefrom | NEKTAR THERAPEUTICS (US) | 2014-12-09 | — | — | US | disclosed |
| US-20140349986-A1 | SUBSTITUTED AMINOINDANES AND ANALOGS THEREOF, AND THE PHARMACEUTICAL USE THEREOF | SANOFI (FR) | 2014-11-27 | — | — | US | disclosed |
| US-8895306-B2 | Oxadiazoline ligands for modulating the expression of exogenous genes via an ecdysone receptor complex | INTREXON CORPORATION (US) | 2014-11-25 | — | — | US | disclosed |
| US-8895306-B2 | Oxadiazoline ligands for modulating the expression of exogenous genes via an ecdysone receptor complex | INTREXON CORPORATION (US) | 2014-11-25 | — | — | US | disclosed |
| US-8895306-B2 | Oxadiazoline ligands for modulating the expression of exogenous genes via an ecdysone receptor complex | INTREXON CORPORATION (US) | 2014-11-25 | — | — | US | disclosed |
| US-8895781-B2 | Transition metal-catalyzed C—H amination using unactivated amines | GEORGETOWN UNIVERSITY (US) | 2014-11-25 | — | — | US | disclosed |
| US-8895781-B2 | Transition metal-catalyzed C—H amination using unactivated amines | GEORGETOWN UNIVERSITY (US) | 2014-11-25 | — | — | US | disclosed |
| US-8889709-B2 | Use of isoQC inhibitors in the treatment and prevention of inflammatory diseases or conditions | PROBIODRUG AG (DE) | 2014-11-18 | — | — | US | disclosed |
| US-20140329831-A1 | NOVEL DOPAMINE D3 RECEPTOR LIGANDS AND PREPARATION AND MEDICAL USES OF THE SAME | INSTITUTE OF PHARMACOLOGY AND TOXICOLOGY ACADEMY OF MILITARY MEDICAL SCIENCE P.L.A. CHINA (CN) | 2014-11-06 | — | — | US | disclosed |
| US-8865741-B2 | Aminoindane compounds and use thereof in treating pain | ASANA BIOSCIENCES, LLC (US) | 2014-10-21 | — | — | US | disclosed |
| US-8865741-B2 | Aminoindane compounds and use thereof in treating pain | ASANA BIOSCIENCES, LLC (US) | 2014-10-21 | — | — | US | disclosed |
| EP-2324032-B1 | INHIBITORS OF BETA-SECRETASE | VITAE PHARMACEUTICALS INC (US) | 2014-10-01 | — | — | EP | disclosed |
| US-8846929-B2 | Substituted-quinoxaline-type piperidine compounds and the uses thereof | PURDUE PHARMA L.P. (US) | 2014-09-30 | — | — | US | disclosed |
| US-8841487-B2 | Phosphine ligands for catalytic reactions | ABBVIE INC. (US) | 2014-09-23 | — | — | US | disclosed |
| US-8829001-B2 | Dopamine D3 receptor ligands and preparation and medical uses of the same | The Institute of Pharmacology and Toxicology Academy of Military Medical Science P.L.A. China (CN) | 2014-09-09 | — | — | US | disclosed |
| US-20140249174-A1 | ARYL-AND HETEROARYLCARBONYL DERIVATIVES OF HEXAHYDROINDENOPYRIDINE AND OCTAHYDROBENZOQUINOLINE | BOEHRINGER-INGELHEIM INTERNATIONAL GMBH (DE) | 2014-09-04 | — | — | US | disclosed |
| US-20140249174-A1 | ARYL-AND HETEROARYLCARBONYL DERIVATIVES OF HEXAHYDROINDENOPYRIDINE AND OCTAHYDROBENZOQUINOLINE | BOEHRINGER-INGELHEIM INTERNATIONAL GMBH (DE) | 2014-09-04 | — | — | US | disclosed |
| US-20140249174-A1 | ARYL-AND HETEROARYLCARBONYL DERIVATIVES OF HEXAHYDROINDENOPYRIDINE AND OCTAHYDROBENZOQUINOLINE | BOEHRINGER-INGELHEIM INTERNATIONAL GMBH (DE) | 2014-09-04 | — | — | US | disclosed |
| US-8822449-B2 | Substituted aminoindanes and analogs thereof, and the pharmaceutical use thereof | SANOFI (FR) | 2014-09-02 | — | — | US | disclosed |
| US-20140213582-A1 | PRMT5 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2014-07-31 | — | — | US | disclosed |
| US-20140205537-A1 | LRRK2 INHIBITORS | ZENOBIA THERAPEUTICS, INC. (US) | 2014-07-24 | — | — | US | disclosed |
| US-8785447-B2 | Use of dopamine D3 receptor ligands for the production of drugs for treating renal function disorders | AbbVie Deutschland GmbH & Co. KG (DE) | 2014-07-22 | — | — | US | disclosed |
| US-8754107-B2 | Aminopyrrolidines as chemokine receptor antagonists | ABBVIE INC. (US) | 2014-06-17 | — | — | US | disclosed |
| US-20140128383-A1 | INHIBITORS OF VIRAL REPLICATION, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTICAL USES | LABORATOIRE BIODIM (FR) | 2014-05-08 | — | — | US | disclosed |
| US-8703115-B2 | Methods for preparing conjugates | NEKTAR THERAPEUTICS (US) | 2014-04-22 | — | — | US | disclosed |
| US-20140107349-A1 | Methods for Preparing Polymeric Reagents | NEKTAR THERAPEUTICS (US) | 2014-04-17 | — | — | US | disclosed |
| US-20140088104-A1 | NOVEL SMALL-MOLECULES AS THERAPEUTICS | BIONOMICS LIMITED (AU) | 2014-03-27 | — | — | US | disclosed |
| US-8669072-B2 | Oxadiazoline ligands for modulating the expression of exogenous genes via an ecdysone receptor complex | INTREXON CORPORATION (US) | 2014-03-11 | — | — | US | disclosed |
| US-8669072-B2 | Oxadiazoline ligands for modulating the expression of exogenous genes via an ecdysone receptor complex | INTREXON CORPORATION (US) | 2014-03-11 | — | — | US | disclosed |
| US-8669072-B2 | Oxadiazoline ligands for modulating the expression of exogenous genes via an ecdysone receptor complex | INTREXON CORPORATION (US) | 2014-03-11 | — | — | US | disclosed |
| US-20140051702-A1 | Use of Aminoindane Compounds in Treating Overactive Bladder and Interstitial Cystitis | ENDO PHARMACEUTICALS INC. (US) | 2014-02-20 | — | — | US | disclosed |
| US-20140051702-A1 | Use of Aminoindane Compounds in Treating Overactive Bladder and Interstitial Cystitis | ENDO PHARMACEUTICALS INC. (US) | 2014-02-20 | — | — | US | disclosed |
| WO-2014028675-A1 | USE OF AMINOINDANE COMPOUNDS IN TREATING OVERACTIVE BLADDER AND INTERSTITIAL CYSTITIS | ENDO PHARMACEUTICALS INC. (US) | 2014-02-20 | — | — | WO | disclosed |
| US-20140045811-A1 | AMIDE, UREA OR SULFONE AMIDE LINKED BENZOTHIAZOLE INHIBITORS OF ENDOTHELIAL LIPASE | BRISTOL-MYERS SQUIBB COMPANY | 2014-02-13 | — | — | US | disclosed |
| US-20140031544-A1 | ARYL-AND HETEROARYLCARBONYL DERIVATIVES OF HEXAHYDROINDENOPYRIDINE AND OCTAHYDROBENZOQUINOLINE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-01-30 | — | — | US | disclosed |
| US-20140031361-A1 | INHIBITORS OF PROTEIN KINASES | PORTOLA PHARMACEUTICALS, INC. | 2014-01-30 | — | — | US | disclosed |
| US-20140031544-A1 | ARYL-AND HETEROARYLCARBONYL DERIVATIVES OF HEXAHYDROINDENOPYRIDINE AND OCTAHYDROBENZOQUINOLINE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-01-30 | — | — | US | disclosed |
| US-20140031544-A1 | ARYL-AND HETEROARYLCARBONYL DERIVATIVES OF HEXAHYDROINDENOPYRIDINE AND OCTAHYDROBENZOQUINOLINE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-01-30 | — | — | US | disclosed |
| WO-2013188771-A2 | CATALYTIC C-H BOND ACTIVATION FOR THE SYNTHESIS OF ETHERS AND THIOETHERS | GEORGETOWN UNIVERSITY (US) | 2013-12-19 | — | — | WO | disclosed |
| US-20130331395-A1 | BRIDGED ARYL PIPERAZINES DERIVATIVES USEFUL FOR THE TREATMENT OF CNS, GI-URINARY AND REPRODUCTIVE DISORDERS | JANSSEN PHARMACEUTICA NV (BE) | 2013-12-12 | — | — | US | disclosed |
| WO-2013169565-A1 | HETEROCYCLIC CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2013-11-14 | — | — | WO | disclosed |
| US-20130303525-A1 | KAPPA OPIOID RECEPTOR AGONISTS | DR. REDDY'S LABORATORIES, INC. (US) | 2013-11-14 | — | — | US | disclosed |
| US-20130303516-A1 | NOVEL TRIAZINE COMPOUNDS | SPHAERA PHARMA PTE. LTD. (SG) | 2013-11-14 | — | — | US | disclosed |
| EP-1601354-B1 | OXADIAZOLINE LIGANDS FOR MODULATING THE EXPRESSION OF EXOGENOUS GENES VIA AN ECDYSONE RECEPTOR COMPLEX | INTREXON CORP (US) | 2013-11-13 | — | — | EP | disclosed |
| EP-1601354-B1 | OXADIAZOLINE LIGANDS FOR MODULATING THE EXPRESSION OF EXOGENOUS GENES VIA AN ECDYSONE RECEPTOR COMPLEX | INTREXON CORP (US) | 2013-11-13 | — | — | EP | disclosed |
| US-8569312-B2 | Biaryl-spiroaminooxzaoline analogues as alpha 2C adrenergic receptor modulators | MERCK SHARP & DOHME CORP. (US) | 2013-10-29 | — | — | US | disclosed |
| US-8569312-B2 | Biaryl-spiroaminooxzaoline analogues as alpha 2C adrenergic receptor modulators | MERCK SHARP & DOHME CORP. (US) | 2013-10-29 | — | — | US | disclosed |
| US-8569535-B2 | Substituted benzoylamino-indan-2-carboxylic acids and related compounds | SANOFI (FR) | 2013-10-29 | — | — | US | disclosed |
| US-8569535-B2 | Substituted benzoylamino-indan-2-carboxylic acids and related compounds | SANOFI (FR) | 2013-10-29 | — | — | US | disclosed |
| US-20130281476-A1 | Modulators of Muscarinic Receptors | VERTEX PHARMACEUTICALS INCORPORATED | 2013-10-24 | — | — | US | disclosed |
| EP-2635563-A1 | CRYSTALLINE FORMS OF HYDROCHLORIDE SALT OF (4A-R,9A-S) -1- (1H - BENZOIMIDAZOLE- 5 -CARBONYL) -2, 3, 4, 4A, 9, 9A - HEXAHYDRO -1H- INDENO [2, 1 -B]PYRIDINE- 6 -CARBONITRILE AND THEIR USE AS HSD 1 INHIBITORS | Boehringer Ingelheim International GmbH (DE) | 2013-09-11 | — | — | EP | disclosed |
| US-8530475-B2 | Serotonin reuptake inhibitors and antagonists of the serotonin 1A receptor; compounds are based on 7,9-diazabicyclo(4.2.2)dec-3-ene ring | JANSSEN PHARMACEUTICA NV | 2013-09-10 | — | — | US | disclosed |
| US-20130225582-A1 | BIARYL-SPIROAMINOOXZAOLINE ANALOGUES AS ALPHA 2C ADRENERGIC RECEPTOR MODULATORS | MERCK SHARP & DOHME CORP. (US) | 2013-08-29 | — | — | US | disclosed |
| US-20130217876-A1 | PHOSPHINE LIGANDS FOR CATALYTIC REACTIONS | ABBVIE INC. (US) | 2013-08-22 | — | — | US | disclosed |
| US-8507488-B2 | Fused nitrogen containing heterocycles and compositions thereof as kinase inhibitors | IRM LLC (BM) | 2013-08-13 | — | — | US | disclosed |
| EP-1819684-B1 | SUBSTITUTED PIPERAZINES AS CB1 ANTAGONISTS | INTERVET INT BV (NL) | 2013-08-07 | — | — | EP | disclosed |
| US-8501944-B2 | Inhibitors of protein kinases | PORTOLA PHARMACEUTICALS, INC. (US) | 2013-08-06 | — | — | US | disclosed |
| US-8497281-B2 | Aryl- and heteroarylcarbonyl derivatives of hexahydroindenopyridine and octahydrobenzoquinoline | VITAE PHARMACEUTICALS, INC. (US) | 2013-07-30 | — | — | US | disclosed |
| US-8497281-B2 | Aryl- and heteroarylcarbonyl derivatives of hexahydroindenopyridine and octahydrobenzoquinoline | VITAE PHARMACEUTICALS, INC. (US) | 2013-07-30 | — | — | US | disclosed |
| US-8497281-B2 | Aryl- and heteroarylcarbonyl derivatives of hexahydroindenopyridine and octahydrobenzoquinoline | VITAE PHARMACEUTICALS, INC. (US) | 2013-07-30 | — | — | US | disclosed |
| US-8497295-B2 | Spiroindoline modulators of muscarinic receptors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-07-30 | — | — | US | disclosed |
| US-8497307-B2 | Aryl guanidine F1F0-ATPase inhibitors and related methods | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2013-07-30 | — | — | US | disclosed |
| US-20130184443-A1 | Methods for Preparing Conjugates | NEKTAR THERAPEUTICS (US) | 2013-07-18 | — | — | US | disclosed |
| US-8486984-B2 | Aminomethyl substituted bicyclic aromatic compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor | ABBOTT GMBH & CO., KG (DE) | 2013-07-16 | — | — | US | disclosed |
| US-20130170016-A1 | PHOTOREFRACTIVE DEVICE CONTAINING A CHROMOPHORE-DOPED POLYMER LAYER AND ITS MANUFACTURING METHOD | NITTO DENKO CORPORATION (JP) | 2013-07-04 | — | — | US | disclosed |
| US-20130170016-A1 | PHOTOREFRACTIVE DEVICE CONTAINING A CHROMOPHORE-DOPED POLYMER LAYER AND ITS MANUFACTURING METHOD | NITTO DENKO CORPORATION (JP) | 2013-07-04 | — | — | US | disclosed |
| US-8476274-B2 | Biaryl spiroaminooxazoline analogues as Alpha2C adrenergic receptor modulators | MERCK SHARP & DOHME CORP. (US) | 2013-07-02 | — | — | US | disclosed |
| US-8476274-B2 | Biaryl spiroaminooxazoline analogues as Alpha2C adrenergic receptor modulators | MERCK SHARP & DOHME CORP. (US) | 2013-07-02 | — | — | US | disclosed |
| US-20130163086-A1 | SYSTEMS AND METHODS FOR IMPROVING THE PERFORMANCE OF A PHOTOREFRACTIVE DEVICE BY UTILIZING ELECTROLYTES | NITTO DENKO CORPORATION (JP) | 2013-06-27 | — | — | US | disclosed |
| US-20130163086-A1 | SYSTEMS AND METHODS FOR IMPROVING THE PERFORMANCE OF A PHOTOREFRACTIVE DEVICE BY UTILIZING ELECTROLYTES | NITTO DENKO CORPORATION (JP) | 2013-06-27 | — | — | US | disclosed |
| US-8450308-B2 | Inhibitors of beta-secretase | VITAE PHARMACEUTICALS, INC. (US) | 2013-05-28 | — | — | US | disclosed |
| US-8450308-B2 | Inhibitors of beta-secretase | VITAE PHARMACEUTICALS, INC. (US) | 2013-05-28 | — | — | US | disclosed |
| US-20130128339-A1 | PHOTOREFRACTIVE COMPOSITION RESPONSIVE TO MULTIPLE LASER WAVELENGTHS ACROSS THE VISIBLE LIGHT SPECTRUM | NITTO DENKO CORPORATION (JP) | 2013-05-23 | — | — | US | disclosed |
| US-20130128339-A1 | PHOTOREFRACTIVE COMPOSITION RESPONSIVE TO MULTIPLE LASER WAVELENGTHS ACROSS THE VISIBLE LIGHT SPECTRUM | NITTO DENKO CORPORATION (JP) | 2013-05-23 | — | — | US | disclosed |
| WO-2013075050-A1 | PHOTOREFRACTIVE DEVICE CONTAINING CARBON NANOTUBE-DOPED POLYMER LAYERS AND ITS MANUFACTURING METHOD | NITTO DENKO CORPORATION (JP) | 2013-05-23 | — | — | WO | disclosed |
| US-8435505-B2 | Pharmaceutical compositions and methods for delivering such compositions | NEKTAR THERAPEUTICS (US) | 2013-05-07 | — | — | US | disclosed |
| US-8436004-B2 | Bicycloaniline derivative | MSD K.K. (JP) | 2013-05-07 | — | — | US | disclosed |
| EP-2586778-A2 | Pyridazinone derivatives useful as glucan synthase inhibitors | Merck Sharp & Dohme Corp. (US) | 2013-05-01 | — | — | EP | disclosed |
| US-8431378-B2 | Aminotransferase, gene encoding the same, and methods of using them | KANEKA CORPORATION (JP) | 2013-04-30 | — | — | US | disclosed |
| EP-1578884-B1 | POLYMER, PRODUCING METHOD THEREOF, AND PHOTOREFRACTIVE COMPOSITION | NITTO DENKO CORP (JP) | 2013-04-24 | — | — | EP | disclosed |
| US-8425784-B2 | Ozonolysis reactions in liquid CO2 and CO2-expanded solvents | UNIVERSITY OF KANSAS (US) | 2013-04-23 | — | — | US | disclosed |
| US-20130096105-A1 | ArylSulfonamide Based Matrix Metalloprotease Inhibitors | NOVARTIS AG (CH) | 2013-04-18 | — | — | US | disclosed |
| US-20130096105-A1 | ArylSulfonamide Based Matrix Metalloprotease Inhibitors | NOVARTIS AG (CH) | 2013-04-18 | — | — | US | disclosed |
| US-20130072468-A1 | SUBSTITUTED PIPERAZINES AS CB1 ANTAGONISTS | GILBERT ERIC J (US) | 2013-03-21 | — | — | US | disclosed |
| US-8389533-B2 | Gem-disubstituted and spirocyclic amino pyridines/pyrimidines as cell cycle inhibitors | AMGEN INC. (US) | 2013-03-05 | — | — | US | disclosed |
| US-8389533-B2 | Gem-disubstituted and spirocyclic amino pyridines/pyrimidines as cell cycle inhibitors | AMGEN INC. (US) | 2013-03-05 | — | — | US | disclosed |
| US-20130045914-A1 | BIARYL SPIROAMINOOXAZOLINE ANALOGUES AS ALPHA2C ADRENERGIC RECEPTOR MODULATORS | MERCK SHARP & DOHME CORP (US) | 2013-02-21 | — | — | US | disclosed |
| US-20130045914-A1 | BIARYL SPIROAMINOOXAZOLINE ANALOGUES AS ALPHA2C ADRENERGIC RECEPTOR MODULATORS | MERCK SHARP & DOHME CORP (US) | 2013-02-21 | — | — | US | disclosed |
| US-8367691-B2 | Modulators of muscarinic receptors | VERTEX PHARMACEUTICAL INCORPORATED (US) | 2013-02-05 | — | — | US | disclosed |
| US-20130029378-A1 | NOVEL ENZYME | ISIS INNOVATION LIMITED (GB) | 2013-01-31 | — | — | US | disclosed |
| US-20130029378-A1 | NOVEL ENZYME | ISIS INNOVATION LIMITED (GB) | 2013-01-31 | — | — | US | disclosed |
| EP-2134342-B1 | MONOCYCLIC ANILIDE SPIROLACTAM CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (US) | 2013-01-30 | — | — | EP | disclosed |
| US-8362063-B2 | Arylsulfonamide based matrix metalloprotease inhibitors | NOVARTIS AG (CH) | 2013-01-29 | — | — | US | disclosed |
| US-8362063-B2 | Arylsulfonamide based matrix metalloprotease inhibitors | NOVARTIS AG (CH) | 2013-01-29 | — | — | US | disclosed |
| US-20130023551-A1 | DISPIRO TETRAOXANE COMPOUNDS | LIVERPOOL SCHOOL OF TROPICAL MEDICINE (GB) | 2013-01-24 | — | — | US | disclosed |
| US-20130023551-A1 | DISPIRO TETRAOXANE COMPOUNDS | LIVERPOOL SCHOOL OF TROPICAL MEDICINE (GB) | 2013-01-24 | — | — | US | disclosed |
| US-8354414-B2 | Substituted bicyclic pyrimidines | CEPHALON, INC (US) | 2013-01-15 | — | — | US | disclosed |
| US-20130005707-A1 | AMINOTRIAZOLOPYRIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | BAHMANYAR SOGOLE (US) | 2013-01-03 | — | — | US | disclosed |
| US-20120318701-A1 | POLYMERIC REAGENTS COMPRISING A TERMINAL VINYLIC GROUP AND CONJUGATES FORMED THEREFROM | NEKTAR THERAPEUTICS (US) | 2012-12-20 | — | — | US | disclosed |
| US-8324213-B2 | Biaryl-spiroaminooxazoline analogues as alpha 2C adrenergic receptor modulators | MERCK SHARP & DOHME CORP. (US) | 2012-12-04 | — | — | US | disclosed |
| US-8324213-B2 | Biaryl-spiroaminooxazoline analogues as alpha 2C adrenergic receptor modulators | MERCK SHARP & DOHME CORP. (US) | 2012-12-04 | — | — | US | disclosed |
| US-20120283243-A1 | Spiroindoline Modulators of Muscarinic Receptors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-11-08 | — | — | US | disclosed |
| US-20120275007-A1 | OPTICAL DEVICES FOR MODULATING LIGHT OF PHOTOREFRACTIVE COMPOSITIONS WITH THERMAL CONTROL | NITTO DENKO CORPORATION (JP) | 2012-11-01 | — | — | US | disclosed |
| US-20120275007-A1 | OPTICAL DEVICES FOR MODULATING LIGHT OF PHOTOREFRACTIVE COMPOSITIONS WITH THERMAL CONTROL | NITTO DENKO CORPORATION (JP) | 2012-11-01 | — | — | US | disclosed |
| US-8288396-B2 | Pyrimidopyrimidoindazole derivative | MSDKK (JP) | 2012-10-16 | — | — | US | disclosed |
| WO-2012137181-A1 | INHIBITORS OF VIRAL REPLICATION, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTICAL USES | LABORATOIRE BIODIM (FR) | 2012-10-11 | — | — | WO | disclosed |
| US-20120258954-A1 | ArylSulfonamide Based Matrix Metalloprotease Inhibitors | NOVARTIS AG (CH) | 2012-10-11 | — | — | US | disclosed |
| US-20120258912-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR DELIVERING SUCH COMPOSITIONS | NEKTAR THERAPEUTICS (US) | 2012-10-11 | — | — | US | disclosed |
| US-20120258954-A1 | ArylSulfonamide Based Matrix Metalloprotease Inhibitors | NOVARTIS AG (CH) | 2012-10-11 | — | — | US | disclosed |
| EP-1951228-B1 | BICYCLIC SPIROHYDANTOIN CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (US) | 2012-10-10 | — | — | EP | disclosed |
| EP-1951051-B1 | SPIROHYDANTOIN TRICYCLIC CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (US) | 2012-10-03 | — | — | EP | disclosed |
| WO-2012129014-A1 | PIPERIDINE CARBOXAMIDE SPIROHYDANTOIN CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2012-09-27 | — | — | WO | disclosed |
| EP-2500345-A1 | 8-AZABICYCLO[3.2.1]OCTANE-8-CARBOXAMIDE DERIVATIVE | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2012-09-19 | — | — | EP | disclosed |
| US-8268948-B2 | Polymeric reagents comprising a terminal vinylic group and conjugates formed therefrom | NEKTAR THERAPEUTICS (US) | 2012-09-18 | — | — | US | disclosed |
| WO-2012119941-A1 | PEPTIDYL NITRILCOMPOUNDS AS PEPTIDASE INHIBITORS | PROZYMEX A/S (DK) | 2012-09-13 | — | — | WO | disclosed |
| EP-2496559-A1 | ARYL- AND HETEROARYLCARBONYL DERIVATIVES OF HEXAHYDROINDENOPYRIDINE AND OCTAHYDROBENZOQUINOLINE | Vitae Pharmaceuticals, Inc. (US) | 2012-09-12 | — | — | EP | disclosed |
| US-8263764-B2 | IL-12 Modulatory compounds | SYNTA PHARMACEUTICALS CORP. (US) | 2012-09-11 | — | — | US | disclosed |
| US-20120225876-A1 | 8-AZABICYCLO[3.2.1]OCTANE-8-CARBOXAMIDE DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2012-09-06 | — | — | US | disclosed |
| US-20120225876-A1 | 8-AZABICYCLO[3.2.1]OCTANE-8-CARBOXAMIDE DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2012-09-06 | — | — | US | disclosed |
| US-8258148-B2 | Spiroindoline modulators of muscarinic receptors | VERTEX PHARMACEUTICAL INCORPORATED (US) | 2012-09-04 | — | — | US | disclosed |
| US-8252275-B2 | Conjugates having a degradable linkage and polymeric reagents useful in preparing such conjugates | NEKTAR THERAPEUTICS (US) | 2012-08-28 | — | — | US | disclosed |
| US-8252512-B2 | Epoxy compound, alkali-developable resin composition, and alkali-developable photosensitive resin composition | ADEKA CORPORATION (JP) | 2012-08-28 | — | — | US | disclosed |
| US-20120214809-A1 | Aminoindane Compounds and Use Thereof in Treating Pain | Libertas Bio, Inc. | 2012-08-23 | — | — | US | disclosed |
| US-20120214809-A1 | Aminoindane Compounds and Use Thereof in Treating Pain | Libertas Bio, Inc. | 2012-08-23 | — | — | US | disclosed |
| WO-2012112876-A1 | PHOTOREFRACTIVE DEVICES HAVING SOL-GEL BUFFER LAYERS AND METHODS OF MANUFACTURING | NITTO DENKO CORPORATION (JP) | 2012-08-23 | — | — | WO | disclosed |
| US-8236805-B2 | Substituted piperazines as CB1 antagonists | INTERVET INC. (US) | 2012-08-07 | — | — | US | disclosed |
| US-8236805-B2 | Substituted piperazines as CB1 antagonists | INTERVET INC. (US) | 2012-08-07 | — | — | US | disclosed |
| US-8232274-B2 | Pyridazinone derivatives useful as glucan synthase inhibitors | ALBANY MOLECULAR RESEARCH, INC. (US) | 2012-07-31 | — | — | US | disclosed |
| US-8232274-B2 | Pyridazinone derivatives useful as glucan synthase inhibitors | ALBANY MOLECULAR RESEARCH, INC. (US) | 2012-07-31 | — | — | US | disclosed |
| US-8222424-B2 | Arylsulfonamide-based matrix metalloprotease inhibitors | NOVARTIS AG (CH) | 2012-07-17 | — | — | US | disclosed |
| US-8222424-B2 | Arylsulfonamide-based matrix metalloprotease inhibitors | NOVARTIS AG (CH) | 2012-07-17 | — | — | US | disclosed |
| US-20120164724-A1 | NOVEL AMINOTRANSFERASE, GENE ENCODING THE SAME, AND METHODS OF USING THEM | KANEKA CORPORATION (JP) | 2012-06-28 | — | — | US | disclosed |
| US-20120157488-A1 | ARYL-AND HETEROARYLCARBONYL DERIVATIVES OF HEXAHYDROINDENOPYRIDINE AND OCTAHYDROBENZOQUINOLINE | BOEHRINGER-INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-21 | — | — | US | disclosed |
| US-20120157488-A1 | ARYL-AND HETEROARYLCARBONYL DERIVATIVES OF HEXAHYDROINDENOPYRIDINE AND OCTAHYDROBENZOQUINOLINE | BOEHRINGER-INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-21 | — | — | US | disclosed |
| US-20120157488-A1 | ARYL-AND HETEROARYLCARBONYL DERIVATIVES OF HEXAHYDROINDENOPYRIDINE AND OCTAHYDROBENZOQUINOLINE | BOEHRINGER-INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-21 | — | — | US | disclosed |
| US-8203780-B2 | Systems and methods for improving the performance of a photorefractive device | NITTO DENKO CORPORATION (JP) | 2012-06-19 | — | — | US | disclosed |
| US-8203780-B2 | Systems and methods for improving the performance of a photorefractive device | NITTO DENKO CORPORATION (JP) | 2012-06-19 | — | — | US | disclosed |
| US-20120134955-A1 | PYRIMIDOPYRIMIDOINDAZOLE DERIVATIVE | MSD K.K. (JP) | 2012-05-31 | — | — | US | disclosed |
| US-20120136016-A1 | 4, 5, 6-TRISUBSTITUTED PYRIMIDINE DERIVATIVES AS FACTOR IXA INHIBITORS | MERCK SHARP & DOHME LLC | 2012-05-31 | — | — | US | disclosed |
| US-20120129867-A1 | INHIBITORS OF PROTEIN KINASES | PORTOLA PHARMACEUTICALS, INC. (US) | 2012-05-24 | — | — | US | disclosed |
| US-20120122869-A1 | TRIZAOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | SYNTA PHARMACEUTICALS CORP. | 2012-05-17 | — | — | US | disclosed |
| US-20120122834-A1 | SMALL MOLECULE CD4 MIMETICS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2012-05-17 | — | — | US | disclosed |
| US-8178559-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-05-15 | — | — | US | disclosed |
| WO-2012061708-A1 | CRYSTALLINE FORMS OF HYDROCHLORIDE SALT OF (4A-R,9A-S) -1- (1H - BENZOIMIDAZOLE- 5 -CARBONYL) -2, 3, 4, 4A, 9, 9A - HEXAHYDRO -1H- INDENO [2, 1 -B] PYRIDINE- 6 -CARBONITRILE AND THEIR USE AS HSD 1 INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-05-10 | — | — | WO | disclosed |
| WO-2012061708-A1 | CRYSTALLINE FORMS OF HYDROCHLORIDE SALT OF (4A-R,9A-S) -1- (1H - BENZOIMIDAZOLE- 5 -CARBONYL) -2, 3, 4, 4A, 9, 9A - HEXAHYDRO -1H- INDENO [2, 1 -B] PYRIDINE- 6 -CARBONITRILE AND THEIR USE AS HSD 1 INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-05-10 | — | — | WO | disclosed |
| EP-2261270-B1 | Polymer, producing method thereof, and photorefractive composition | NITTO DENKO CORP (JP) | 2012-05-09 | — | — | EP | disclosed |
| US-8173699-B2 | Compounds for the treatment of inflammatory diseases | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-05-08 | — | — | US | disclosed |
| US-20120107914-A1 | MICROBIAL ACTIVITY IMPROVEMENT AGENT, MICROBIAL ACTIVITY IMPROVEMENT METHOD, AND BIOLOGICAL WASTE TREATMENT METHOD | SUMITOMO HEAVY INDUSTRIES, LTD. (JP) | 2012-05-03 | — | — | US | disclosed |
| EP-1606264-B1 | MONOCYCLIC ANILIDE SPIROHYDANTOIN CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (US) | 2012-05-02 | — | — | EP | disclosed |
| US-8148390-B2 | Monocyclic anilide spirolactam CGRP receptor antagonists | Merck, Sharp & Dohme, Corp. (US) | 2012-04-03 | — | — | US | disclosed |
| US-8148390-B2 | Monocyclic anilide spirolactam CGRP receptor antagonists | Merck, Sharp & Dohme, Corp. (US) | 2012-04-03 | — | — | US | disclosed |
| EP-2433937-A1 | Substituted-quinoxaline-type-piperidine compounds and the uses thereof | Purdue Pharma LP (US) | 2012-03-28 | — | — | EP | disclosed |
| EP-2434340-A1 | Systems and methods for improving the performance of a photorefractive device | Nitto Denko Corporation (JP) | 2012-03-28 | — | — | EP | disclosed |
| EP-2433935-A1 | Substituted-quinoxaline-type-piperidine compounds and the uses thereof | Purdue Pharma LP (US) | 2012-03-28 | — | — | EP | disclosed |
| EP-2433936-A1 | Substituted-quinoxaline-type-piperidine compounds and the uses thereof | Purdue Pharma LP (US) | 2012-03-28 | — | — | EP | disclosed |
| WO-2012037143-A1 | PHOTOREFRACTIVE DEVICE CONTAINING A CHROMOPHORE-DOPED POLYMER LAYER AND ITS MANUFACTURING METHOD | NITTO DENKO CORPORATION (JP) | 2012-03-22 | — | — | WO | disclosed |
| US-8133705-B2 | Aminotransferase, gene encoding the same, and method of using them | KANEKA CORPORATION (JP) | 2012-03-13 | — | — | US | disclosed |
| WO-2012031025-A1 | SYSTEMS AND METHODS FOR IMPROVING THE PERFORMANCE OF A PHOTOREFRACTIVE DEVICE BY UTILIZING ELECTROLYTES | NITTO DENKO CORPORATION (JP) | 2012-03-08 | — | — | WO | disclosed |
| US-8129423-B2 | 1-Adamantan-2-yl-3-benzyl-1,3-dihydro-imidazol-2-one; 11beta-hydroxysteroid dehydrogenases (11beta-HSD) inhibitor; antidiabetic, hypotensive, hypoglycemic agent; resist hyperglycemia provoked by obesity or stress; | HOFFMAN-LA ROCHE INC. (US) | 2012-03-06 | — | — | US | disclosed |
| EP-2126625-B1 | SYSTEMS AND METHODS FOR IMPROVING THE PERFORMANCE OF A PHOTOREFRACTIVE DEVICE | NITTO DENKO CORP (JP) | 2012-02-22 | — | — | EP | disclosed |
| WO-2012018342-A1 | PHOTOREFRACTIVE COMPOSITION RESPONSIVE TO MULTIPLE LASER WAVELENGTHS ACROSS THE VISIBLE LIGHT SPECTRUM | NITTO DENKO CORPORATION (JP) | 2012-02-09 | — | — | WO | disclosed |
| US-8110578-B2 | Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway | SIGNAL PHARMACEUTICALS, LLC (US) | 2012-02-07 | — | — | US | disclosed |
| US-20120022252-A1 | PHOSPHINE LIGANDS FOR CATALYTIC REACTIONS | ABBOTT LABORATORIES (US) | 2012-01-26 | — | — | US | disclosed |
| US-20110319423-A1 | NOVEL DOPAMINE D3 RECEPTOR LIGANDS AND PREPARATION AND MEDICAL USES OF THE SAME | Institute of Pharmacology and Toxicology Academy of Military Medical Science, P.L.A (CN) | 2011-12-29 | — | — | US | disclosed |
| US-8071771-B2 | Bicyclic spirohydantoin CGRP receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2011-12-06 | — | — | US | disclosed |
| US-8071771-B2 | Bicyclic spirohydantoin CGRP receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2011-12-06 | — | — | US | disclosed |
| US-8071770-B2 | Spirohydantoin aryl CGRP receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2011-12-06 | — | — | US | disclosed |
| US-8071770-B2 | Spirohydantoin aryl CGRP receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2011-12-06 | — | — | US | disclosed |
| US-20110294798-A1 | IL-12 MODULATORY COMPOUNDS | SYNTA PHARMACEUTICALS CORP. (US) | 2011-12-01 | — | — | US | disclosed |
| EP-1613368-B1 | CARBOXAMIDE SPIROHYDANTOIN CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (US) | 2011-11-30 | — | — | EP | disclosed |
| EP-2278973-B1 | GEM-DISUBSTITUTED AND SPIROCYCLIC AMINO PYRIDINES/PYRIMIDINES AS CELL CYCLE INHIBITORS | AMGEN INC (US) | 2011-11-02 | — | — | EP | disclosed |
| US-20110262845-A1 | METHOD FOR MODULATING LIGHT OF PHOTOREFRACTIVE COMPOSITION WITHOUT EXTERNAL BIAS VOLTAGE | NITTO DENKO CORPORATION | 2011-10-27 | — | — | US | disclosed |
| US-20110262845-A1 | METHOD FOR MODULATING LIGHT OF PHOTOREFRACTIVE COMPOSITION WITHOUT EXTERNAL BIAS VOLTAGE | NITTO DENKO CORPORATION | 2011-10-27 | — | — | US | disclosed |
| US-20110263560-A1 | Organic Compounds | NOVARTIS AG (CH) | 2011-10-27 | — | — | US | disclosed |
| US-20110251200-A1 | ARYL GUANIDINE F1F0-ATPASE INHIBITORS AND RELATED METHODS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2011-10-13 | — | — | US | disclosed |
| US-20110251207-A1 | BIARYL-SPIROAMINOOXAZOLINE ANALOGUES AS ALPHA 2C ADRENERGIC RECEPTOR MODULATORS | MERCK SHARP & DOHME CORP. (US) | 2011-10-13 | — | — | US | disclosed |
| US-20110251207-A1 | BIARYL-SPIROAMINOOXAZOLINE ANALOGUES AS ALPHA 2C ADRENERGIC RECEPTOR MODULATORS | MERCK SHARP & DOHME CORP. (US) | 2011-10-13 | — | — | US | disclosed |
| US-20110218192-A1 | Inhibitors Of Beta-Secretase | VITAE PHARMACEUTICALS, INC. (US) | 2011-09-08 | — | — | US | disclosed |
| US-20110218192-A1 | Inhibitors Of Beta-Secretase | VITAE PHARMACEUTICALS, INC. (US) | 2011-09-08 | — | — | US | disclosed |
| US-20110213146-A1 | Transition Metal-Catalyzed C-H Amination Using Unactivated Amines | GEORGETOWN UNIVERSITY (US) | 2011-09-01 | — | — | US | disclosed |
| US-20110213146-A1 | Transition Metal-Catalyzed C-H Amination Using Unactivated Amines | GEORGETOWN UNIVERSITY (US) | 2011-09-01 | — | — | US | disclosed |
| US-8008525-B2 | For the 14273 peroxisome proliferator activated receptor; antidiabetic agents, hyperlipidemia, obesity or anorexia; receptor binding assay; drug screening kits | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-08-30 | — | — | US | disclosed |
| US-20110201590-A1 | SUBSTITUTED AMINOINDANES AND ANALOGS THEREOF, AND THE PHARMACEUTICAL USE THEREOF | SANOFI-AVENTIS (FR) | 2011-08-18 | — | — | US | disclosed |
| EP-1794146-B1 | TRICYCLIC ANILIDE SPIROHYDANTOIN CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (US) | 2011-08-03 | — | — | EP | disclosed |
| US-7985356-B2 | Non-linear optical device sensitive to green laser | NITTO DENKO CORPORATION (JP) | 2011-07-26 | — | — | US | disclosed |
| US-7985356-B2 | Non-linear optical device sensitive to green laser | NITTO DENKO CORPORATION (JP) | 2011-07-26 | — | — | US | disclosed |
| US-20110178041-A1 | HETEROCYCLIC BIARYL DERIVATIVE AND PDE INHIBITOR COMPRISING SAME AS ACTIVE INGREDIENT | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2011-07-21 | — | — | US | disclosed |
| EP-2344157-A1 | NOVEL INHIBITORS | Probiodrug AG (DE) | 2011-07-20 | — | — | EP | disclosed |
| EP-1605936-B1 | ARYL SPIROHYDANTOIN CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (US) | 2011-07-20 | — | — | EP | disclosed |
| EP-2344158-A1 | Use of isoQC inhibitors | Probiodrug AG (DE) | 2011-07-20 | — | — | EP | disclosed |
| EP-2342178-A1 | SUBSTITUTED AMINOINDANES AND ANALOGS THEREOF, AND THE PHARMACEUTICAL USE THEREOF | Sanofi-Aventis (FR) | 2011-07-13 | — | — | EP | disclosed |
| US-20110166133-A1 | FUSED NITROGEN CONTAINING HETEROCYCLES AND COMPOSITIONS THEREOF AS KINASE INHIBITORS | IRM LLC (BM) | 2011-07-07 | — | — | US | disclosed |
| US-7968540-B2 | Spirohydantoin tricyclic CGRP receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2011-06-28 | — | — | US | disclosed |
| US-7968540-B2 | Spirohydantoin tricyclic CGRP receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2011-06-28 | — | — | US | disclosed |
| US-7964691-B2 | 5,5-diallyl-2,2-dimethyl-1,3-dioxane as monomer units; polymerization catalysts; heat resistance | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2011-06-21 | — | — | US | disclosed |
| US-20110144146-A1 | Aminomethyl Substituted Bicyclic Aromatic Compounds Suitable for Treating Disorders That Respond to Modulation of the Dopamine D3 Receptor | ABBOTT GMBH & CO. KG | 2011-06-16 | — | — | US | disclosed |
| US-7960369-B2 | Receptor function regulator | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-06-14 | — | — | US | disclosed |
| US-20110135601-A1 | BICYCLOANILINE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. | 2011-06-09 | — | — | US | disclosed |
| US-20110136800-A1 | ARYL-AND HETEROARYLCARBONYL DERIVATIVES OF HEXAHYDROINDENOPYRIDINE AND OCTAHYDROBENZOQUINOLINE | Boehringer Ingelheim International GmbH Vitae Pharmaceuticals | 2011-06-09 | — | — | US | disclosed |
| US-20110136800-A1 | ARYL-AND HETEROARYLCARBONYL DERIVATIVES OF HEXAHYDROINDENOPYRIDINE AND OCTAHYDROBENZOQUINOLINE | Boehringer Ingelheim International GmbH Vitae Pharmaceuticals | 2011-06-09 | — | — | US | disclosed |
| US-20110136800-A1 | ARYL-AND HETEROARYLCARBONYL DERIVATIVES OF HEXAHYDROINDENOPYRIDINE AND OCTAHYDROBENZOQUINOLINE | Boehringer Ingelheim International GmbH Vitae Pharmaceuticals | 2011-06-09 | — | — | US | disclosed |
| WO-2011059021-A1 | 8-AZABICYCLO[3.2.1]OCTANE-8-CARBOXAMIDE DERIVATIVE | 大日本住友製薬株式会社 (JP) | 2011-05-19 | — | — | WO | disclosed |
| US-7943760-B2 | Non-nucleotide composition for inhibiting platelet aggregation | INSPIRE PHARMACEUTICALS, INC. (US) | 2011-05-17 | — | — | US | disclosed |
| WO-2011057054-A1 | ARYL- AND HETEROARYLCARBONYL DERIVATIVES OF HEXAHYDROINDENOPYRIDINE AND OCTAHYDROBENZOQUINOLINE | VITAE PHARMACEUTICALS, INC. (US) | 2011-05-12 | — | — | WO | disclosed |
| WO-2011057054-A1 | ARYL- AND HETEROARYLCARBONYL DERIVATIVES OF HEXAHYDROINDENOPYRIDINE AND OCTAHYDROBENZOQUINOLINE | VITAE PHARMACEUTICALS, INC. (US) | 2011-05-12 | — | — | WO | disclosed |
| EP-1606286-B1 | BENODIAZEPINE SPIROHYDANTOIN CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (US) | 2011-05-11 | — | — | EP | disclosed |
| US-20110097305-A1 | Gem-Disubstituted and Spirocyclic Amino Pyridines/Pyrimidines as Cell Cycle Inhibitors | AMGEN INC. (US) | 2011-04-28 | — | — | US | disclosed |
| US-20110097305-A1 | Gem-Disubstituted and Spirocyclic Amino Pyridines/Pyrimidines as Cell Cycle Inhibitors | AMGEN INC. (US) | 2011-04-28 | — | — | US | disclosed |
| EP-2308851-A1 | Imidazolone and imidazolidinone derivatives as 11B-HSD1 inhibitors for the treatment of diabetes | F. Hoffmann-La Roche AG (CH) | 2011-04-13 | — | — | EP | disclosed |
| US-7919508-B2 | 3-piperidinylisochroman-5-ols as dopamine agonists | AVENTIS PHARMACEUTICALS INC. (US) | 2011-04-05 | — | — | US | disclosed |
| US-7919508-B2 | 3-piperidinylisochroman-5-ols as dopamine agonists | AVENTIS PHARMACEUTICALS INC. (US) | 2011-04-05 | — | — | US | disclosed |
| US-20110053920-A1 | SUBSTITUTED BICYCLIC PYRIMIDINES | CEPHALON, INC. (US) | 2011-03-03 | — | — | US | disclosed |
| US-7879834-B2 | spiro[indoline-3,4'-piperidine] derivatives, used for the treatment of nervous system disorders, chronic obstructive pulmonary disease, asthma, urinary incontinence, vision defects, Alzheimer's disiease, obesity or as analgesics and antidepressants | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-02-01 | — | — | US | disclosed |
| US-20110014186-A1 | ARYLSULFONAMIDE-BASED MATRIX METALLOPROTEASE INHIBITORS | NOVARTIS AG (CH) | 2011-01-20 | — | — | US | disclosed |
| US-20110014186-A1 | ARYLSULFONAMIDE-BASED MATRIX METALLOPROTEASE INHIBITORS | NOVARTIS AG (CH) | 2011-01-20 | — | — | US | disclosed |
| US-7863270-B2 | IL-12 modulatory compounds | SYNTA PHARMACEUTICALS CORP. (US) | 2011-01-04 | — | — | US | disclosed |
| EP-1951251-B1 | SPIROHYDANTOIN ARYL CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (US) | 2010-12-29 | — | — | EP | disclosed |
| US-7858635-B2 | Spiro compounds as modulators of muscarinic receptors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-12-28 | — | — | US | disclosed |
| EP-2261270-A1 | Polymer, producing method thereof, and photorefractive composition | Nitto Denko Corporation (JP) | 2010-12-15 | — | — | EP | disclosed |
| US-20100311746-A1 | MODULATORS OF MUSCARINIC RECEPTORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-12-09 | — | — | US | disclosed |
| US-20100311720-A1 | Spiroindoline Modulators of Muscarinic Receptors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-12-09 | — | — | US | disclosed |
| US-7842686-B2 | CGRP receptor antagonists | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-11-30 | — | — | US | disclosed |
| US-7842686-B2 | CGRP receptor antagonists | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-11-30 | — | — | US | disclosed |
| US-20100298138-A1 | Aminoazoline and Urea Derivatives for Combating Animal Pests | BASF SE (DE) | 2010-11-25 | — | — | US | disclosed |
| US-20100285544-A1 | Novel aminotransferase, gene encoding the same, and method of using them | KANEKA CORPORATION (JP) | 2010-11-11 | — | — | US | disclosed |
| US-7820837-B2 | ethyl {6-[(3-phenoxybenzyl)oxy]-3,4-dihydronaphthalen-1-yl}acetate; having a GPR40 receptor function modulating action and being useful as an insulin secretagogue or a pharmaceutical agent for the prophylaxis or treatment of diabetes | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-10-26 | — | — | US | disclosed |
| EP-2233479-A1 | DISPIRO TETRAOXANE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MALARIA AND/OR CANCER | Liverpool School of Tropical Medicine (GB) | 2010-09-29 | — | — | EP | disclosed |
| EP-2230312-A1 | Probe compound for detecting and isolating enzymes and means and methods using the same | Helmholtz-Zentrum für Infektionsforschung GmbH (DE) | 2010-09-22 | — | — | EP | disclosed |
| US-20100222601-A1 | SYNTHESIS OF CYCLOPENTADIENE DERIVATIVES | BASELL POLYOLEFINE GMBH (DE) | 2010-09-02 | — | — | US | disclosed |
| US-20100222601-A1 | SYNTHESIS OF CYCLOPENTADIENE DERIVATIVES | BASELL POLYOLEFINE GMBH (DE) | 2010-09-02 | — | — | US | disclosed |
| US-7786141-B2 | Dihydrospiroindene modulators of muscarinic receptors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-08-31 | — | — | US | disclosed |
| US-20100216781-A1 | mTOR KINASE INHIBITORS FOR ONCOLOGY INDICATIONS AND DISEASES ASSOCIATED WITH THE mTOR/PI3K/AKT PATHWAY | SIGNAL PHARMACEUTICALS, LLC | 2010-08-26 | — | — | US | disclosed |
| US-20100216726-A1 | Substituted-Quinoxaline-Type Piperidine Compounds and the Uses Thereof | PURDUE PHARMA L.P. (US) | 2010-08-26 | — | — | US | disclosed |
| US-20100216726-A1 | Substituted-Quinoxaline-Type Piperidine Compounds and the Uses Thereof | PURDUE PHARMA L.P. (US) | 2010-08-26 | — | — | US | disclosed |
| US-20100204224-A1 | AZACYCLIC COMPOUNDS AS INHIBITORS OF SENSORY NEURONE SPECIFIC SODIUM CHANNELS | VERNALIS R & D LIMITED (GB) | 2010-08-12 | — | — | US | disclosed |
| US-20100197913-A1 | NON-NUCLEOTIDE COMPOSITION FOR INHIBITING PLATELET AGGREGATION | PLOURDE JR ROBERT | 2010-08-05 | — | — | US | disclosed |
| US-20100190767-A1 | Compounds for the treatment of inflammatory diseases | ANDERSKEWITZ RALF | 2010-07-29 | — | — | US | disclosed |
| US-7750010-B2 | Tricyclic anilide spirohydantion CGRP receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2010-07-06 | — | — | US | disclosed |
| US-7750010-B2 | Tricyclic anilide spirohydantion CGRP receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2010-07-06 | — | — | US | disclosed |
| US-7749980-B2 | Non-nucleotide compositions and method for treating pain | INSPIRE PHARMACEUTICALS, INC. (US) | 2010-07-06 | — | — | US | disclosed |
| US-7749981-B2 | Drug-eluting stents coated with non-nucleotide P2Y12 receptor antagonist compound | INSPIRE PHARMACEUTICALS, INC. (US) | 2010-07-06 | — | — | US | disclosed |
| US-7741351-B2 | Compounds which potentiate glutamate receptor and uses thereof in medicine | GLAXO GROUP LIMITED (GB) | 2010-06-22 | — | — | US | disclosed |
| US-20100152216-A1 | MONOCYCLIC ANILIDE SPIROLACTAM CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LLC | 2010-06-17 | — | — | US | disclosed |
| US-20100152216-A1 | MONOCYCLIC ANILIDE SPIROLACTAM CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LLC | 2010-06-17 | — | — | US | disclosed |
| US-7736548-B2 | Non-linear optical device with long grating persistency | NITTO DENKO CORPORATION (JP) | 2010-06-15 | — | — | US | disclosed |
| US-7736548-B2 | Non-linear optical device with long grating persistency | NITTO DENKO CORPORATION (JP) | 2010-06-15 | — | — | US | disclosed |
| EP-2049532-B1 | CGRP RECEPTOR ANTAGONISTS | VERTEX PHARMA (US) | 2010-06-02 | — | — | EP | disclosed |
| EP-1685135-B1 | TETRAHYDRO-FURO[3,4-d]DIOXOLE COMPOUNDS AND COMPOSITIONS AND METHOD FOR INHIBITING PLATELET AGGREGATION | INSPIRE PHARMACEUTICALS INC (US) | 2010-05-26 | — | — | EP | disclosed |
| US-7723381-B2 | Compounds for the treatment of inflammatory diseases | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-05-25 | — | — | US | disclosed |
| US-20100125086-A1 | USE OF ISOQC INHIBITORS | PROBIODRUG AG (DE) | 2010-05-20 | — | — | US | disclosed |
| US-20100119475-A1 | NOVEL INHIBITORS OF GLUTAMINYL CYCLASE | PROBIODRUG AG (DE) | 2010-05-13 | — | — | US | disclosed |
| US-20100113462-A1 | SUBSTITUTED BENZOYLAMINO-INDAN-2-CARBOXYLIC ACIDS AND RELATED COMPOUNDS | SANOFI-AVENTIS (FR) | 2010-05-06 | — | — | US | disclosed |
| US-20100113462-A1 | SUBSTITUTED BENZOYLAMINO-INDAN-2-CARBOXYLIC ACIDS AND RELATED COMPOUNDS | SANOFI-AVENTIS (FR) | 2010-05-06 | — | — | US | disclosed |
| US-20100113436-A1 | DISPIRO TETRAOXANE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MALARIA AND/OR CANCER | LIVERPOOL SCHOOL OF TROPICAL MEDICINE (GB) | 2010-05-06 | — | — | US | disclosed |
| US-20100113436-A1 | DISPIRO TETRAOXANE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MALARIA AND/OR CANCER | LIVERPOOL SCHOOL OF TROPICAL MEDICINE (GB) | 2010-05-06 | — | — | US | disclosed |
| US-20100099789-A1 | METHOD FOR MODULATING LIGHT OF PHOTOREFRACTIVE COMPOSITION | NITTO DENKO CORPORATION (JP) | 2010-04-22 | — | — | US | disclosed |
| US-20100099789-A1 | METHOD FOR MODULATING LIGHT OF PHOTOREFRACTIVE COMPOSITION | NITTO DENKO CORPORATION (JP) | 2010-04-22 | — | — | US | disclosed |
| US-7700597-B2 | Substituted piperazines as CB1 antagonists | SCHERING CORPORATION (US) | 2010-04-20 | — | — | US | disclosed |
| US-7700597-B2 | Substituted piperazines as CB1 antagonists | SCHERING CORPORATION (US) | 2010-04-20 | — | — | US | disclosed |
| WO-2010042473-A1 | BIARYL SPIROAMINOOXAZOLINE ANALOGUES AS ALPHA2C ADRENERGIC RECEPTOR MODULATORS | SCHERING CORPORATION (US) | 2010-04-15 | — | — | WO | disclosed |
| WO-2010042475-A1 | SPIROAMINOOXAZOLINE ANALOGUES AS ALPHA2C ADRENERGIC RECEPTOR MODULATORS | SCHERING CORPORATION (US) | 2010-04-15 | — | — | WO | disclosed |
| WO-2010038803-A1 | 2-INDOLEACRYLAMIDE ANALOGUE | 持田製薬株式会社 (JP) | 2010-04-08 | — | — | WO | disclosed |
| US-20100086958-A1 | NOVEL ENZYME | ISIS INNOVATION LIMITED (GB) | 2010-04-08 | — | — | US | disclosed |
| US-20100086958-A1 | NOVEL ENZYME | ISIS INNOVATION LIMITED (GB) | 2010-04-08 | — | — | US | disclosed |
| EP-1807393-B1 | DIARYLSULFONES AS 5-HT2A ANTAGONISTS | MERCK SHARP & DOHME (GB) | 2010-03-31 | — | — | EP | disclosed |
| WO-2010026209-A1 | Use of isoQC inhibitors | PROBIODRUG AG (DE) | 2010-03-11 | — | — | WO | disclosed |
| WO-2010025856-A1 | SUBSTITUTED AMINOINDANES AND ANALOGS THEREOF, AND THE PHARMACEUTICAL USE THEREOF | SANOFI-AVENTIS (FR) | 2010-03-11 | — | — | WO | disclosed |
| WO-2010026212-A1 | NOVEL INHIBITORS | PROBIODRUG AG (DE) | 2010-03-11 | — | — | WO | disclosed |
| WO-2010028159-A2 | TRANSITION METAL-CATALYZED C-H AMINATION USING UNACTIVATED AMINES | GEORGETOWN UNIVERSITY (US) | 2010-03-11 | — | — | WO | disclosed |
| WO-2010028159-A2 | TRANSITION METAL-CATALYZED C-H AMINATION USING UNACTIVATED AMINES | GEORGETOWN UNIVERSITY (US) | 2010-03-11 | — | — | WO | disclosed |
| US-20100060975-A1 | SYSTEMS AND METHODS FOR IMPROVING THE PERFORMANCE OF A PHOTOREFRACTIVE DEVICE | NITTO DENKO CORPORATION (JP) | 2010-03-11 | — | — | US | disclosed |
| US-20100060975-A1 | SYSTEMS AND METHODS FOR IMPROVING THE PERFORMANCE OF A PHOTOREFRACTIVE DEVICE | NITTO DENKO CORPORATION (JP) | 2010-03-11 | — | — | US | disclosed |
| US-20100056432-A1 | TEMPLATE-FIXED PEPTIDOMIMETICS WITH ANTIBACTERIAL ACTIVITY | POLYPHOR LTD. (CH) | 2010-03-04 | — | — | US | disclosed |
| EP-1749001-B1 | 3-PIPERIDINYLISOCHROMAN-5-OLS AS DOPAMINE AGONISTS | AVENTIS PHARMA INC (US) | 2010-03-03 | — | — | EP | disclosed |
| WO-2010021680-A2 | INHIBITORS OF BETA-SECRETASE | VITAE PHARMACEUTICALS, INC. (US) | 2010-02-25 | — | — | WO | disclosed |
| US-20100048707-A1 | Polymeric Reagents Comprising a Terminal Vinylic Group and Conjugates Formed Therefrom | NEKTAR THERAPEUTICS (US) | 2010-02-25 | — | — | US | disclosed |
| US-20100029607-A1 | Substituted Piperazines as CB1 Antagonists | SCHERING CORPORATION | 2010-02-04 | — | — | US | disclosed |
| US-20100029607-A1 | Substituted Piperazines as CB1 Antagonists | SCHERING CORPORATION | 2010-02-04 | — | — | US | disclosed |
| US-20100015551-A1 | NOVEL EPOXY COMPOUND, ALKALI-DEVELOPABLE RESIN COMPOSITION, AND ALKALI-DEVELOPABLE PHOTOSENSITIVE RESIN COMPOSITION | ADEKA CORPORATION (JP) | 2010-01-21 | — | — | US | disclosed |
| US-7618969-B2 | Compounds which potentiate glutamate receptor and uses thereof in medicine | GLAXO GROUP LIMITED (GB) | 2009-11-17 | — | — | US | disclosed |
| US-20090281080-A1 | Spirohydantoin Tricyclic CGRP Receptor Antagonists | MERCK SHARP & DOHME LLC | 2009-11-12 | — | — | US | disclosed |
| US-20090281080-A1 | Spirohydantoin Tricyclic CGRP Receptor Antagonists | MERCK SHARP & DOHME LLC | 2009-11-12 | — | — | US | disclosed |
| WO-2009126584-A1 | GEM-DISUBSTITUTED AND SPIROCYCLIC AMINO PYRIDINES/PYRIMIDINES AS CELL CYCLE INHIBITORS | AMGEN INC. (US) | 2009-10-15 | — | — | WO | disclosed |
| EP-1529038-B1 | BENZOTHIAZOLE DERIVATIVES HAVING BETA-2-ADRENORECEPTOR AGONIST ACTIVITY | NOVARTIS AG (CH) | 2009-10-07 | — | — | EP | disclosed |
| WO-2009118292-A1 | ARYLSULFONAMIDE-BASED MATRIX METALLOPROTEASE INHIBITORS | NOVARTIS AG (CH) | 2009-10-01 | — | — | WO | disclosed |
| EP-2104665-A2 | IMIDAZOLONE AND IMIDAZOLIDINONE DERIVATIVES AS 11B-HSD1 INHIBITORS FOR DIABETES | F. Hoffmann-Roche AG (CH) | 2009-09-30 | — | — | EP | disclosed |
| US-20090239870-A1 | Spirohydantoin Aryl Cgrp Receptor Antagonists | MERCK SHARP & DOHME LLC | 2009-09-24 | — | — | US | disclosed |
| US-20090239870-A1 | Spirohydantoin Aryl Cgrp Receptor Antagonists | MERCK SHARP & DOHME LLC | 2009-09-24 | — | — | US | disclosed |
| US-7592445-B2 | Non-nucleotide composition and method for inhibiting platelet aggregation | INSPIRE PHARMACEUTICALS, INC. (US) | 2009-09-22 | — | — | US | disclosed |
| US-20090221535-A1 | IMMUNOGENIC COMPOSITIONS FOR GRAM POSITIVE BACTERIA SUCH AS STREPTOCOCCUS AGALACTIAE | MERCK SHARP & DOHME LLC | 2009-09-03 | — | — | US | disclosed |
| US-20090221535-A1 | IMMUNOGENIC COMPOSITIONS FOR GRAM POSITIVE BACTERIA SUCH AS STREPTOCOCCUS AGALACTIAE | MERCK SHARP & DOHME LLC | 2009-09-03 | — | — | US | disclosed |
| US-7582604-B2 | Template-fixed peptidomimetics with antibacterial activity | POLYPHOR LTD. (CH) | 2009-09-01 | — | — | US | disclosed |
| EP-1601354-A4 | OXADIAZOLINE LIGANDS FOR MODULATING THE EXPRESSION OF EXOGENOUS GENES VIA AN ECDYSONE RECEPTOR COMPLEX | INTREXON CORP (US) | 2009-08-12 | — | — | EP | disclosed |
| US-7572819-B2 | Compounds which potentiate glutamate receptor and uses thereof in medicine | GLAXO GROUP LIMITED (GB) | 2009-08-11 | — | — | US | disclosed |
| US-20090197186-A1 | OPTICAL DEVICES RESPONSIVE TO BLUE LASER AND METHOD OF MODULATING LIGHT | NITTO DENKO CORPORATION (JP) | 2009-08-06 | — | — | US | disclosed |
| US-20090197186-A1 | OPTICAL DEVICES RESPONSIVE TO BLUE LASER AND METHOD OF MODULATING LIGHT | NITTO DENKO CORPORATION (JP) | 2009-08-06 | — | — | US | disclosed |
| US-20090186882-A1 | CGRP RECEPTOR ANTAGONISTS | VERTEX PHARMACEUTICALS INCORPORATED | 2009-07-23 | — | — | US | disclosed |
| US-20090186882-A1 | CGRP RECEPTOR ANTAGONISTS | VERTEX PHARMACEUTICALS INCORPORATED | 2009-07-23 | — | — | US | disclosed |
| US-20090176757-A1 | Bicyclic Spirohydantoin CGRP Receptor Antagonists | MERCK SHARP & DOHME LLC | 2009-07-09 | — | — | US | disclosed |
| US-20090176757-A1 | Bicyclic Spirohydantoin CGRP Receptor Antagonists | MERCK SHARP & DOHME LLC | 2009-07-09 | — | — | US | disclosed |
| US-20090170861-A1 | Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors | SCHERING CORPORATION AND ALBANY MOLECULAR RESEARCH, INC. | 2009-07-02 | — | — | US | disclosed |
| US-20090170861-A1 | Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors | SCHERING CORPORATION AND ALBANY MOLECULAR RESEARCH, INC. | 2009-07-02 | — | — | US | disclosed |
| US-20090170824-A1 | Diarylsulfones as 5-HT2A Antagonists | CASTRO PINEIRO JOSE LUIS | 2009-07-02 | — | — | US | disclosed |
| US-20090149514-A1 | OXADIAZOLINE LIGANDS FOR MODULATING THE EXPRESSION OF EXOGENOUS GENES VIA AN ECDYSONE RECEPTOR COMPLEX | INTREXON CORPORATION | 2009-06-11 | — | — | US | disclosed |
| US-20090149514-A1 | OXADIAZOLINE LIGANDS FOR MODULATING THE EXPRESSION OF EXOGENOUS GENES VIA AN ECDYSONE RECEPTOR COMPLEX | INTREXON CORPORATION | 2009-06-11 | — | — | US | disclosed |
| US-20090149514-A1 | OXADIAZOLINE LIGANDS FOR MODULATING THE EXPRESSION OF EXOGENOUS GENES VIA AN ECDYSONE RECEPTOR COMPLEX | INTREXON CORPORATION | 2009-06-11 | — | — | US | disclosed |
| US-7544825-B1 | Preparation of siloxy-bridged metallocenes | BASELL POLYOLEFINE GMBH (DE) | 2009-06-09 | — | — | US | disclosed |
| US-7544825-B1 | Preparation of siloxy-bridged metallocenes | BASELL POLYOLEFINE GMBH (DE) | 2009-06-09 | — | — | US | disclosed |
| US-7538168-B2 | Halogen substituted metallocene compounds for olefin polymerization | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2009-05-26 | — | — | US | disclosed |
| US-7538168-B2 | Halogen substituted metallocene compounds for olefin polymerization | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2009-05-26 | — | — | US | disclosed |
| US-20090118498-A1 | OZONOLYSIS REACTIONS IN LIQUID CO2 AND CO2-EXPANDED SOLVENTS | ARCHER DANIELS MIDLAND COMPANY | 2009-05-07 | — | — | US | disclosed |
| WO-2009038006-A1 | RANDOM COPOLYMER AND PRODUCTION PROCESS THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2009-03-26 | — | — | WO | disclosed |
| WO-2009038031-A1 | BLOCK COPOLYMER AND PRODUCTION PROCESS THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2009-03-26 | — | — | WO | disclosed |
| WO-2009027820-A2 | SUBSTITUTED-QUINOXALINE-TYPE-PIPERIDINE COMPOUNDS AND THE USES THEREOF | PURDUE PHARMA L.P. (DE) | 2009-03-05 | — | — | WO | disclosed |
| US-20090052009-A1 | NON-LINEAR OPTICAL DEVICE SENSITIVE TO GREEN LASER | NITTO DENKO CORPORATION (JP) | 2009-02-26 | — | — | US | disclosed |
| US-20090052009-A1 | NON-LINEAR OPTICAL DEVICE SENSITIVE TO GREEN LASER | NITTO DENKO CORPORATION (JP) | 2009-02-26 | — | — | US | disclosed |
| EP-1458747-B1 | TEMPLATE-FIXED PEPTIDOMIMETICS AS INHIBITORS OF SERINE PROTEASES | POLYPHOR LTD (CH) | 2009-02-11 | — | — | EP | disclosed |
| US-20090012093-A1 | Receptor Function Regulator | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-01-08 | — | — | US | disclosed |
| US-7468393-B2 | Diarylsulfones as 5-HT2A antagonists | MERCK SHARP & DOHME LTD. (GB) | 2008-12-23 | — | — | US | disclosed |
| WO-2008151211-A1 | SUBSTITUTED BENZOYLAMINO-INDAN-2-CARBOXYLIC ACIDS AND RELATED COMPOUNDS | SANOFI-AVENTIS (FR) | 2008-12-11 | — | — | WO | disclosed |
| US-7446216-B2 | Halogen substituted metallocene compounds for olefin polymerization | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2008-11-04 | — | — | US | disclosed |
| US-7446216-B2 | Halogen substituted metallocene compounds for olefin polymerization | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2008-11-04 | — | — | US | disclosed |
| US-7438993-B2 | Electrolyte for lithium battery and lithium battery comprising same | SAMSUNG SDI CO., LTD. (KR) | 2008-10-21 | — | — | US | disclosed |
| US-7438993-B2 | Electrolyte for lithium battery and lithium battery comprising same | SAMSUNG SDI CO., LTD. (KR) | 2008-10-21 | — | — | US | disclosed |
| US-20080255210-A1 | 1-Benzyl-3-[3-(3,5-dimethyl-phenyl)-5,5-dimethyl-[1,2,4]oxadiazol-4-yl]-urea; nuclear receptor-based inducible gene expression system | HORMANN ROBERT EUGENE | 2008-10-16 | — | — | US | disclosed |
| US-20080255210-A1 | 1-Benzyl-3-[3-(3,5-dimethyl-phenyl)-5,5-dimethyl-[1,2,4]oxadiazol-4-yl]-urea; nuclear receptor-based inducible gene expression system | HORMANN ROBERT EUGENE | 2008-10-16 | — | — | US | disclosed |
| US-20080255210-A1 | 1-Benzyl-3-[3-(3,5-dimethyl-phenyl)-5,5-dimethyl-[1,2,4]oxadiazol-4-yl]-urea; nuclear receptor-based inducible gene expression system | HORMANN ROBERT EUGENE | 2008-10-16 | — | — | US | disclosed |
| US-7429274-B2 | Agent and method for the oxidative coloring of keratin fibers | WELLA AG (DE) | 2008-09-30 | — | — | US | disclosed |
| WO-2008115381-A1 | PYRIDAZINONE DERIVATIVES USEFUL AS GLUCAN SYNTHASE INHIBITORS | SCHERING CORPORATION (US) | 2008-09-25 | — | — | WO | disclosed |
| WO-2008112159-A2 | MONOCYCLIC ANILIDE SPIROLACTAM CGRP RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2008-09-18 | — | — | WO | disclosed |
| US-20080214755-A1 | OLEFIN-DIENE COPOLYMER AND PROCESS FOR PRODUCING THE SAME | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2008-09-04 | — | — | US | disclosed |
| US-7417024-B2 | Template-fixed peptidomimetics as inhibitors of serine proteases | POLYPHOR LTD. (CH) | 2008-08-26 | — | — | US | disclosed |
| US-20080194648-A1 | COMPOUNDS WHICH POTENTIATE GLUTAMATE RECEPTOR AND USES THEREOF IN MEDICINE | GLAXO GROUP LIMITED | 2008-08-14 | — | — | US | disclosed |
| WO-2008091716-A1 | SYSTEMS AND METHODS FOR IMPROVING THE PERFORMANCE OF A PHOTOREFRACTIVE DEVICE | NITTO DENKO CORPORATION (JP) | 2008-07-31 | — | — | WO | disclosed |
| US-20080176883-A1 | Antiinflammtory, antiproliferative, anticancer agents; (3-Hydroxy-pyrrolidin-1-yl)-(3-trifluoromethyl-7,8-dihydro-5H-[1,6]naphthyridin-6-yl)-methanone | ABBVIE INC. | 2008-07-24 | — | — | US | disclosed |
| EP-1943261-A2 | DRUG-ELUTING STENTS COATED WITH NON-NUCLEOTIDE P2Y12 RECEPTOR ANTAGONIST COMPOUND | Inspire Pharmaceuticals, Inc. (US) | 2008-07-16 | — | — | EP | disclosed |
| US-20080167378-A1 | Receptor Function Regulation Agent | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-07-10 | — | — | US | disclosed |
| WO-2008071527-A2 | SYNTHESIS OF CYCLOPENTADIENE DERIVATIVES | BASELL POLYOLEFINE GMBH (DE) | 2008-06-19 | — | — | WO | disclosed |
| EP-1608627-B1 | BICYCLIC ANILIDE SPIROHYDANTOIN CGRP RECEPTOR ANTAGONISTS | MERCK & CO INC (US) | 2008-05-07 | — | — | EP | disclosed |
| US-7368438-B2 | Non-nucleotide compositions and method for inhibiting platelet aggregation | INSPIRE PHARMACEUTICALS, INC. (US) | 2008-05-06 | — | — | US | disclosed |
| US-20080103304-A1 | NON-NUCLEOTIDE COMPOSITION AND METHOD FOR INHIBITING PLATELET AGGREGATION | PLOURDE ROBERT JR | 2008-05-01 | — | — | US | disclosed |
| US-20080103183-A1 | NEW IMIDAZOLONE AND IMIDAZOLIDINONE DERIVATIVES AS 11B-HSD1 INHIBITORS | HOFFMANN-LA ROCHE INC. | 2008-05-01 | — | — | US | disclosed |
| WO-2008046758-A2 | IMIDAZOLONE AND IMIDAZOLIDINONE DERIVATIVES AS 11B-HSD1 INHIBITORS FOR DIABETES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-04-24 | — | — | WO | disclosed |
| EP-1910374-A1 | AZACYCLIC COMPOUNDS AS INHIBITORS OF SENSORY NEURONE SPECIFIC SODIUM CHANNELS | Vernalis (R&D) Limited (GB) | 2008-04-16 | — | — | EP | disclosed |
| WO-2008038030-A2 | DISPIRO TETRAOXANE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MALARIA AND/OR CANCER | LIVERPOOL SCHOOL OF TROPICAL MEDICINE (GB) | 2008-04-03 | — | — | WO | disclosed |
| US-20080070919-A1 | BRIDGED ARYL PIPERAZINES DERIVATIVES USEFUL FOR THE TREATMENT OF CNS, GI-URINARY AND REPRODUCTIVE DISORDERS | CREIGHTON CHRISTOPHER J | 2008-03-20 | — | — | US | disclosed |
| US-7335648-B2 | Non-nucleotide composition and method for inhibiting platelet aggregation | INSPIRE PHARMACEUTICALS, INC. (US) | 2008-02-26 | — | — | US | disclosed |
| US-20080039603-A1 | NON-LINEAR OPTICAL DEVICE WITH LONG GRATING PERSISTENCY | NITTO DENKO CORPORATION (JP) | 2008-02-14 | — | — | US | disclosed |
| US-20080039603-A1 | NON-LINEAR OPTICAL DEVICE WITH LONG GRATING PERSISTENCY | NITTO DENKO CORPORATION (JP) | 2008-02-14 | — | — | US | disclosed |
| CN-101124235-A | Olefin polymerization catalyst system and method of using same | EXXONMOBIL CHEM PATENTS INC (US) | 2008-02-13 | — | — | CN | disclosed |
| EP-1883637-A2 | NON-NUCLEOTIDE COMPOSITION AND METHOD FOR INHIBITING PLATELET AGGREGATION | Inspire Pharmaceuticals, Inc. (US) | 2008-02-06 | — | — | EP | disclosed |
| WO-2008013774-A2 | NON-LINEAR OPTICAL DEVICE WITH LONG GRATING PERSISTENCY | NITTO DENKO CORPORATION (JP) | 2008-01-31 | — | — | WO | disclosed |
| WO-2008013775-A2 | NON-LINEAR OPTICAL DEVICE SENSITIVE TO GREEN LASER | NITTO DENKO CORPORATION (JP) | 2008-01-31 | — | — | WO | disclosed |
| WO-2008011190-A1 | CGRP RECEPTOR ANTAGONISTS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-01-24 | — | — | WO | disclosed |
| US-20080015383-A1 | PROCESS FOR THE PREPARATION OF DELAPRIL | DIPHARMA FRANCIS S.R.L. (IT) | 2008-01-17 | — | — | US | disclosed |
| US-20080015383-A1 | PROCESS FOR THE PREPARATION OF DELAPRIL | DIPHARMA FRANCIS S.R.L. (IT) | 2008-01-17 | — | — | US | disclosed |
| US-20080015179-A1 | Modulators of muscarinic receptors | VERTEX PHARMACEUTICALS INCORPORATED | 2008-01-17 | — | — | US | disclosed |
| EP-1878740-A1 | A process for the preparation of delapril | Dipharma Francis S.r.l. (IT) | 2008-01-16 | — | — | EP | disclosed |
| US-7317058-B2 | (Meth)acrylate polymer and non-linear optical device material composition | NITTO DENKO CORPORATION (JP) | 2008-01-08 | — | — | US | disclosed |
| US-7317058-B2 | (Meth)acrylate polymer and non-linear optical device material composition | NITTO DENKO CORPORATION (JP) | 2008-01-08 | — | — | US | disclosed |
| US-20070287731-A1 | 1-Benzyl-3-[3-(3,5-dimethyl-phenyl)-5,5-dimethyl-[1,2,4]oxadiazol-4-yl]-urea; nuclear receptor-based inducible gene expression system | RHEOGENE, INC. (DE CORPORATION) | 2007-12-13 | — | — | US | disclosed |
| US-20070287731-A1 | 1-Benzyl-3-[3-(3,5-dimethyl-phenyl)-5,5-dimethyl-[1,2,4]oxadiazol-4-yl]-urea; nuclear receptor-based inducible gene expression system | RHEOGENE, INC. (DE CORPORATION) | 2007-12-13 | — | — | US | disclosed |
| US-20070287731-A1 | 1-Benzyl-3-[3-(3,5-dimethyl-phenyl)-5,5-dimethyl-[1,2,4]oxadiazol-4-yl]-urea; nuclear receptor-based inducible gene expression system | RHEOGENE, INC. (DE CORPORATION) | 2007-12-13 | — | — | US | disclosed |
| US-7304162-B2 | Regulating and tailoring expression levels; such as N-[3-(4-chloro-phenyl)-5,5-dimethyl-[1,2,4]oxadiazol-4-yl]-3-ethyl-benzamide | INTREXON CORPORATION (US) | 2007-12-04 | — | — | US | disclosed |
| US-7304162-B2 | Regulating and tailoring expression levels; such as N-[3-(4-chloro-phenyl)-5,5-dimethyl-[1,2,4]oxadiazol-4-yl]-3-ethyl-benzamide | INTREXON CORPORATION (US) | 2007-12-04 | — | — | US | disclosed |
| US-7304162-B2 | Regulating and tailoring expression levels; such as N-[3-(4-chloro-phenyl)-5,5-dimethyl-[1,2,4]oxadiazol-4-yl]-3-ethyl-benzamide | INTREXON CORPORATION (US) | 2007-12-04 | — | — | US | disclosed |
| WO-2007137168-A2 | BRIDGED ARYL PIPERAZINES DERIVATIVES USEFUL FOR THE TREATMENT OF CNS, GI-URINARY AND REPRODUCTIVE DISORDERS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-11-29 | — | — | WO | disclosed |
| US-7288559-B2 | Carboxamide spirohydantoin CGRP receptor antagonists | MERCK + CO, INC. (US) | 2007-10-30 | — | — | US | disclosed |
| US-7288559-B2 | Carboxamide spirohydantoin CGRP receptor antagonists | MERCK + CO, INC. (US) | 2007-10-30 | — | — | US | disclosed |
| US-20070249586-A1 | Benzothiazole derivatives having beta-2-adrenoreceptor agonist activity | CUENOUD BERNARD | 2007-10-25 | — | — | US | disclosed |
| WO-2007100369-A2 | NON-LINEAR OPTICAL DEVICE MATERIAL COMPOSITION | NITTO DENKO CORPORATION (JP) | 2007-09-07 | — | — | WO | disclosed |
| US-20070203205-A1 | Diarylsulfones as 5-HT2A antagonists | MERCK SHARP & DOHME (UK) LIMITED (GB) | 2007-08-30 | — | — | US | disclosed |
| US-20070203218-A1 | Compounds Which Potentiate Glutamate Receptor And Uses Thereof In Medicine | GLAXO GROUP LIMITED (GB) | 2007-08-30 | — | — | US | disclosed |
| US-7253146-B2 | Template-fixed peptidomimetics with antimicrobial activity | POLYPHOR LTD (CH) | 2007-08-07 | — | — | US | disclosed |
| US-7250121-B2 | Non-linear optical device material composition | NITTO DENKO CORPORATION (JP) | 2007-07-31 | — | — | US | disclosed |
| US-7250121-B2 | Non-linear optical device material composition | NITTO DENKO CORPORATION (JP) | 2007-07-31 | — | — | US | disclosed |
| EP-1807393-A1 | DIARYLSULFONES AS 5-HT2A ANTAGONISTS | Merck Sharp & Dohme Limited (GB) | 2007-07-18 | — | — | EP | disclosed |
| US-20070161638-A1 | Compounds which potentiate glutamate receptor and uses thereof in medicine | GLAXO GROUP LIMITED (GB) | 2007-07-12 | — | — | US | disclosed |
| US-7241551-B2 | Positive-working resist composition | FUJIFILM CORPORATION (JP) | 2007-07-10 | — | — | US | disclosed |
| US-7241551-B2 | Positive-working resist composition | FUJIFILM CORPORATION (JP) | 2007-07-10 | — | — | US | disclosed |
| WO-2007070038-A1 | HALOGEN SUBSTITUTED METALLOCENE COMPOUNDS FOR OLEFIN POLYMERIZATION | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2007-06-21 | — | — | WO | disclosed |
| US-20070130702-A1 | Dyeing process using a specific compound containing active methylene and a compound chosen from a specific aldehyde, a specific ketone, a quinone and a diiminoisoindoline or 3-aminoisoindolone derivative | L'OREAL S.A. | 2007-06-14 | — | — | US | disclosed |
| US-20070135593-A1 | Halogen substituted metallocene compounds for olefin polymerization | EXXONMOBIL CHEMICAL PATENTS INC. | 2007-06-14 | — | — | US | disclosed |
| US-20070135593-A1 | Halogen substituted metallocene compounds for olefin polymerization | EXXONMOBIL CHEMICAL PATENTS INC. | 2007-06-14 | — | — | US | disclosed |
| WO-2007061695-A2 | BICYCLIC SPIROHYDANTOIN CGRP RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2007-05-31 | — | — | WO | disclosed |
| WO-2007061694-A2 | SPIROHYDANTOIN TRICYCLIC CGRP RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2007-05-31 | — | — | WO | disclosed |
| US-20070123544-A1 | Non-nucleotide compositions and method for treating pain | INSPIRE PHARMACEUTICALS, INC. | 2007-05-31 | — | — | US | disclosed |
| WO-2007061676-A2 | SPIROHYDANTOIN ARYL CGRP RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2007-05-31 | — | — | WO | disclosed |
| WO-2007056217-A2 | DRUG-ELUTING STENTS COATED WITH NON-NUCLEOTIDE P2Y12 RECEPTOR ANTAGONIST COMPOUND | INSPIRE PHARMACEUTICALS, INC. (US) | 2007-05-18 | — | — | WO | disclosed |
| US-20070111982-A1 | Calcitonin Gene-Related Peptide, CGRP; treatment of migraine and cluster headache; 2,5-dioxo-3',4'-dihydro-spiro(imidazolidine-4,2'(1'H)-naphthalene)-6'-carboxamides | MERCK SHARP & DOHME LLC | 2007-05-17 | — | — | US | disclosed |
| US-20070111982-A1 | Calcitonin Gene-Related Peptide, CGRP; treatment of migraine and cluster headache; 2,5-dioxo-3',4'-dihydro-spiro(imidazolidine-4,2'(1'H)-naphthalene)-6'-carboxamides | MERCK SHARP & DOHME LLC | 2007-05-17 | — | — | US | disclosed |
| US-7217740-B2 | Diarylsulfones as 5-HT2A antagonists | MERCK SHARP AND DOHME | 2007-05-15 | — | — | US | disclosed |
| WO-2007051255-A1 | PROCESS FOR THE PREPARATION OF COMPOUNDS CONTAINING AN AZACYCLIC RING SYSTEM | THE UNIVERSITY OF SYDNEY (AU) | 2007-05-10 | — | — | WO | disclosed |
| US-7214697-B2 | 2-Oxo-benzimidazolyl substituted ethanolamine derivatives and their use as β3 agonists | ELI LILLY AND COMPANY (US) | 2007-05-08 | — | — | US | disclosed |
| WO-2007050441-A2 | (METH)ACRYLATE POLYMER AND NON-LINEAR OPTICAL DEVICE MATERIAL COMPOSITION | NITTO DENKO CORPORATION (JP) | 2007-05-03 | — | — | WO | disclosed |
| US-20070099955-A1 | 3-PIPERIDINYLISOCHROMAN-5-OLS AS DOPAMINE AGONISTS | AVENTIS PHARMACEUTICALS INC. (US) | 2007-05-03 | — | — | US | disclosed |
| US-20070099955-A1 | 3-PIPERIDINYLISOCHROMAN-5-OLS AS DOPAMINE AGONISTS | AVENTIS PHARMACEUTICALS INC. (US) | 2007-05-03 | — | — | US | disclosed |
| US-7205293-B2 | Benodiazepine spirohydantoin CGRP receptor antagonists | MERCK & CO., INC. (US) | 2007-04-17 | — | — | US | disclosed |
| US-7205293-B2 | Benodiazepine spirohydantoin CGRP receptor antagonists | MERCK & CO., INC. (US) | 2007-04-17 | — | — | US | disclosed |
| US-7204857-B1 | Dyeing method using a specific active methylene compound and a compound selected among a specific aldehyde, a specific ketone, a quinone and a di-imino-isoindoline or 3-amino-isoindolone derivative | L'OREAL S.A. (FR) | 2007-04-17 | — | — | US | disclosed |
| US-20070079452-A1 | Agent and method for the oxidative coloring of keratin fibers | Wella GmbH (DE) | 2007-04-12 | — | — | US | disclosed |
| US-7202251-B2 | Bicyclic anilide spirohydantoin CGRP receptor antagonists | MERCK & CO., INC. (US) | 2007-04-10 | — | — | US | disclosed |
| US-7202251-B2 | Bicyclic anilide spirohydantoin CGRP receptor antagonists | MERCK & CO., INC. (US) | 2007-04-10 | — | — | US | disclosed |
| EP-1506955-B1 | Bicyclic amino acids as pharmaceuticals agents | WARNER LAMBERT CO (US) | 2007-03-28 | — | — | EP | disclosed |
| CN-1933841-A | Pharmaceutical composition comprising a benzodiazepine derivative and an inhibitor of the rsv fusion protein | ARROW THERAPEUTICS LTD (GB) | 2007-03-21 | — | — | CN | disclosed |
| US-7192954-B2 | Monocyclic anilide spirohydantoin CGRP receptor antagonists | MERCK & CO., INC. (US) | 2007-03-20 | — | — | US | disclosed |
| US-7192954-B2 | Monocyclic anilide spirohydantoin CGRP receptor antagonists | MERCK & CO., INC. (US) | 2007-03-20 | — | — | US | disclosed |
| US-7189722-B2 | Aryl spirohydantoin CGRP receptor antagonists | MERCK & CO., INC. (US) | 2007-03-13 | — | — | US | disclosed |
| US-7189722-B2 | Aryl spirohydantoin CGRP receptor antagonists | MERCK & CO., INC. (US) | 2007-03-13 | — | — | US | disclosed |
| US-7186781-B2 | Fullerene-containing polymer, producing method thereof, and photorefractive composition | NITTO DENKO CORPORATION (JP) | 2007-03-06 | — | — | US | disclosed |
| US-7186781-B2 | Fullerene-containing polymer, producing method thereof, and photorefractive composition | NITTO DENKO CORPORATION (JP) | 2007-03-06 | — | — | US | disclosed |
| US-7183311-B2 | NF-κB inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2007-02-27 | — | — | US | disclosed |
| US-20070043023-A1 | Modulators of muscarinic receptors | VERTEX PHARMACEUTICALS INCORPORATED | 2007-02-22 | — | — | US | disclosed |
| WO-2007007069-A1 | AZACYCLIC COMPOUNDS AS INHIBITORS OF SENSORY NEURONE SPECIFIC SODIUM CHANNELS | VERNALIS (R & D) LIMITED (GB) | 2007-01-18 | — | — | WO | disclosed |
| US-20060281711-A1 | IL-12 modulatory compounds | SYNTA PHARMACEUTICALS CORP. (US) | 2006-12-14 | — | — | US | disclosed |
| WO-2006124662-A1 | IL-12 MODULATORY COMPOUNDS | SYNTA PHARMACEUTICALS CORP. (US) | 2006-11-23 | — | — | WO | disclosed |
| US-7138542-B2 | Method of treating tinnitus | WARNER LAMBERT COMPANY (US) | 2006-11-21 | — | — | US | disclosed |
| WO-2006119507-A2 | NON-NUCLEOTIDE COMPOSITION AND METHOD FOR INHIBITING PLATELET AGGREGATION | INSPIRE PHARMACEUTICALS, INC. (US) | 2006-11-09 | — | — | WO | disclosed |
| EP-1709040-A2 | FIVE-MEMBERED HETEROCYCLIC COMPOUNDS AS INHIBITORS OF SRC FAMILY PROTEIN KINASE | Sirenade Pharmaceuticals AG (DE) | 2006-10-11 | — | — | EP | disclosed |
| EP-1685135-A1 | TETRAHYDRO-FURO¬3,4-D|DIOXOLE COMPOUNDS AND COMPOSITIONS AND METHOD FOR INHIBITING PLATELET AGGREGATION | Inspire Pharmaceuticals, Inc. (US) | 2006-08-02 | — | — | EP | disclosed |
| US-7071195-B2 | Amine and amide derivatives as ligands for the neuropeptide Y Y5 receptor useful in the treatment of obesity and other disorders | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2006-07-04 | — | — | US | disclosed |
| EP-1250342-B1 | BRIDGED METALLOCENE COMPOUNDS AS OLEFIN-POLYMERIZATION CATALYSTS | POLIMERI EUROPA SPA (IT) | 2006-06-28 | — | — | EP | disclosed |
| US-20060121086-A1 | Drug-eluting stents coated with non-nucleotide P2Y12 receptor antagonist compound | INSPIRE PHARMACEUTICALS, INC. | 2006-06-08 | — | — | US | disclosed |
| US-20060106075-A1 | Benzothiazole derivatives having beta-2-adrenoreceptor agonist activity | NOVARTIS AG (CH) | 2006-05-18 | — | — | US | disclosed |
| US-20060100281-A1 | Method of treating tinnitus | DOOLEY DAVID J | 2006-05-11 | — | — | US | disclosed |
| US-7026505-B2 | Method of treating tinnitus | WARNER-LAMBERT COMPANY (US) | 2006-04-11 | — | — | US | disclosed |
| US-20060052445-A1 | Diarylsulfones as 5-HT2A antagonists | MERCK SHARP & DOHME (UK) LIMITED (GB) | 2006-03-09 | — | — | US | disclosed |
| US-20060052388-A1 | Amine and amide derivatives as ligands for the neuropeptide Y Y5 receptor useful in the treatment of obesity and other disorders | DAX SCOTT L | 2006-03-09 | — | — | US | disclosed |
| WO-2006021805-A1 | DIARYLSULFONES AS 5-HT2A ANTAGONISTS | MERCK SHARP & DOHME LIMITED (GB) | 2006-03-02 | — | — | WO | disclosed |
| US-6984703-B1 | Bridged metallocene compounds as olefin-polymerization catalysts | POLIMERI EUROPA S.P.A. (IT) | 2006-01-10 | — | — | US | disclosed |
| EP-1601354-A2 | OXADIAZOLINE LIGANDS FOR MODULATING THE EXPRESSION OF EXOGENOUS GENES VIA AN ECDYSONE RECEPTOR COMPLEX | RheoGene Holdings Inc. (US) | 2005-12-07 | — | — | EP | disclosed |
| US-20050267134-A1 | Non-nucleotide composition and method for inhibiting platelet aggregation | INSPIRE PHARMACEUTICALS, INC. | 2005-12-01 | — | — | US | disclosed |
| US-20050239693-A1 | Template-fixed peptidomimetics with antibacterial activity | POLYPHOR LTD. | 2005-10-27 | — | — | US | disclosed |
| US-20050187145-A1 | Template-fixed peptidommetics as inhibitors of serine proteases | POLYPHOR LTD. (CH) | 2005-08-25 | — | — | US | disclosed |
| WO-2005068458-A2 | FIVE-MEMBERED HETEROCYCLIC COMPOUNDS AS INHIBITORS OF SRC FAMILY PROTEIN KINASE | SIRENADE PHARMACEUTICALS AG (DE) | 2005-07-28 | — | — | WO | disclosed |
| US-20050159388-A1 | Non-nucleotide compositions and method for inhibiting platelet aggregation | INSPIRE PHARMACEUTICALS, INC. | 2005-07-21 | — | — | US | disclosed |
| EP-1555264-A1 | Five-membered heterocyclic compounds as inhibitors of SRC family protein kinase. | Sireen AG (DE) | 2005-07-20 | — | — | EP | disclosed |
| EP-1048658-B1 | ALICYCLIC ACYLATED HETEROCYCLIC DERIVATIVES | SANKYO CO (JP) | 2005-06-15 | — | — | EP | disclosed |
| EP-1529038-A1 | BENZOTHIAZOLE DERIVATIVES HAVING BETA-2-ADRENORECEPTOR AGONIST ACTIVITY | Novartis AG (CH) | 2005-05-11 | — | — | EP | disclosed |
| WO-2005040174-A1 | TETRAHYDRO-FURO`3,4-D!DIOXOLE COMPOUNDS AND COMPOSITIONS AND METHOD FOR INHIBITING PLATELET AGGREGATION | INSPIRE PHARMACEUTICALS, INC. (US) | 2005-05-06 | — | — | WO | disclosed |
| WO-2005039590-A1 | NON-NUCLEOTIDE COMPOSITIONS AND METHOD FOR TREATING PAIN | INSPIRE PHARMACEUTICALS, INC. (US) | 2005-05-06 | — | — | WO | disclosed |
| EP-1357910-B1 | METHOD FOR PREVENTING AND TREATING VISCERAL PAIN AND GASTROINTESTINAL DISORDERS | WARNER LAMBERT CO (US) | 2005-04-27 | — | — | EP | disclosed |
| EP-1226110-B1 | BICYCLIC AMINO ACIDS AS PHARMACEUTICAL AGENTS | WARNER LAMBERT CO (US) | 2005-04-20 | — | — | EP | disclosed |
| EP-1514541-A1 | Use of bicyclic amino acids for preventing and treating visceral pain and gastrointestinal disorders | Warner-Lambert Company LLC (US) | 2005-03-16 | — | — | EP | disclosed |
| WO-2005017126-A2 | OXADIAZOLINE LIGANDS FOR MODULATING THE EXPRESSION OF EXOGENOUS GENES VIA AN ECDYSONE RECEPTOR COMPLEX | RHEOGENE HOLDINGS, INC. (US) | 2005-02-24 | — | — | WO | disclosed |
| EP-1506955-A1 | Bicyclic amino acids as pharmaceuticals agents | Warner-Lambert Company LLC (US) | 2005-02-16 | — | — | EP | disclosed |
| EP-1493742-A1 | Amine and amide derivatives as ligands for the neuropeptide Y Y5 receptor useful in the treatment of obesity and other disorders | Ortho-Mcneil Pharmaceutical, Inc. (US) | 2005-01-05 | — | — | EP | disclosed |
| US-20040266876-A1 | Method for preventing and treating visceral pain and gastrointestinal disorders | CHOVET MARIA (FR) | 2004-12-30 | — | — | US | disclosed |
| US-6835751-B2 | Bicyclic amino acids as pharmaceutical agents | WARNER-DAMBERT COMPANY LLC | 2004-12-28 | — | — | US | disclosed |
| EP-1469841-A1 | ALPHA 2 DELTA LIGANDS TO TREAT TINNITUS | WARNER-LAMBERT COMPANY (US) | 2004-10-27 | — | — | EP | disclosed |
| EP-1458747-A1 | TEMPLATE-FIXED PEPTIDOMIMETICS AS INHIBITORS OF SERINE PROTEASES | Polyphor Ltd. (CH) | 2004-09-22 | — | — | EP | disclosed |
| EP-0935608-A4 | CYTOTOXIC PEPTIDES | BIOMOLECULAR RES INST LTD (AU) | 2004-09-15 | — | — | EP | disclosed |
| US-20040171651-A1 | Regulating and tailoring expression levels; such as N-[3-(4-chloro-phenyl)-5,5-dimethyl-[1,2,4]oxadiazol-4-yl]-3-ethyl-benzamide | RHEOGENE, INC. (DE CORPORATION) | 2004-09-02 | — | — | US | disclosed |
| US-20040171066-A1 | Template-fixed peptidomimetics with antimicrobial activity | POLYPHOR LTD. (CH) | 2004-09-02 | — | — | US | disclosed |
| US-6784208-B2 | BICYCLIC FUSED HYDROCARBON RINGS SUBSTITUTED WITH AMINOMETHYL AND CARBOXYMETHYL GROUPS ON SAME POSITION OF RING; 3-AMINOMETHYL-BICYCLO(3.2.0)HEPTANE-3-ACETIC ACID FOR EXAMPLE | WARNER-LAMBERT COMPANY | 2004-08-31 | — | — | US | disclosed |
| US-20040152779-A1 | Bicyclic amino acids as pharmaceutical agents | BRYANS JUSTIN STEPHEN (GB) | 2004-08-05 | — | — | US | disclosed |
| WO-2004016601-A1 | BENZOTHIAZOLE DERIVATIVES HAVING BETA-2-ADRENORECEPTOR AGONIST ACTIVITY | NOVARTIS AG (CH) | 2004-02-26 | — | — | WO | disclosed |
| US-6689906-B1 | Bicyclic amino acids as pharmaceutical agents | WARNER-LAMBERT COMPANY | 2004-02-10 | — | — | US | disclosed |
| EP-1357910-A2 | METHOD FOR PREVENTING AND TREATING VISCERAL PAIN AND GASTROINTESTINAL DISORDERS | Warner-Lambert Company LLC (US) | 2003-11-05 | — | — | EP | disclosed |
| US-6642251-B1 | Antitumor, 2-indolinone derivatives | SUGEN, INC. | 2003-11-04 | — | — | US | disclosed |
| US-20030199510-A1 | Geometrically restricted 2-indolinone derivatives as modulators of protein kinase activity | SUGEN, INC. | 2003-10-23 | — | — | US | disclosed |
| US-20030176504-A1 | Method of treating tinnitus | DOOLEY DAVID JAMES (US) | 2003-09-18 | — | — | US | disclosed |
| CN-1121398-C | Alicyclic acylated heterocyclic derivatives | SANKYO CO (JP) | 2003-09-17 | — | — | CN | disclosed |
| US-6620829-B2 | Administering a therapeutically effective amount of a GABA analog having characteristic of being an inhibitor of cartilage damage, or a pharmaceutically acceptable salt | WARNER-LAMBERT COMPANY | 2003-09-16 | — | — | US | disclosed |
| WO-2003063845-A1 | ALPHA 2 DELTA LIGANDS TO TREAT TINNITUS | WARNER-LAMBERT COMPANY LLC (US) | 2003-08-07 | — | — | WO | disclosed |
| US-20030148877-A1 | Metallocenes and catalysts for olefin-polymerisation | BASELL TECHNOLOGY COMPANY BV (NL) | 2003-08-07 | — | — | US | disclosed |
| EP-0865419-B1 | INDANE DIMER COMPOUNDS AND THEIR PHARMACEUTICAL USE | VENANTIUS LTD (IE) | 2003-08-06 | — | — | EP | disclosed |
| WO-2003054000-A1 | TEMPLATE-FIXED PEPTIDOMIMETICSAS INHIBITORS OF SERINE PROTEASES | POLYPHOR LTD. (CH) | 2003-07-03 | — | — | WO | disclosed |
| US-6525072-B1 | Prevention and treatment of cellular disorders such as cancer | SUGEN, INC. | 2003-02-25 | — | — | US | disclosed |
| EP-0952978-B1 | METALLOCENES AND CATALYSTS FOR OLEFIN-POLYMERISATION | BASELL POLYOLEFINE GMBH (DE) | 2003-01-22 | — | — | EP | disclosed |
| US-20020161047-A1 | Method for preventing and treating visceral pain and gastrointestinal disorders | WARNER-LAMBERT COMPANY | 2002-10-31 | — | — | US | disclosed |
| EP-1250342-A1 | BRIDGED METALLOCENE COMPOUNDS AS OLEFIN-POLYMERIZATION CATALYSTS | Polimeri Europa S.p.A. (IT) | 2002-10-23 | — | — | EP | disclosed |
| US-6451724-B1 | BIS(N-METHYL-5,10-DIHYDROINDENO(1,2-B)INDOL-10 -YL)TITANIUM DICHLORIDE | BASELL TECHNOLOGY COMPANY BV (NL) | 2002-09-17 | — | — | US | disclosed |
| US-20020115715-A1 | Amine and amide derivatives as ligands for the neuropeptide Y Y5 receptor useful in the treatment of obesity and other disorders | DAX SCOTT L (US) | 2002-08-22 | — | — | US | disclosed |
| WO-2002058680-A2 | USE OF BICYLIC AMINO ACIDS FOR PREVENTING AND TREATING VISCERAL PAIN AND GASTROINTESTINAL DISORDERS | WARNER-LAMBERT COMPANY LLC (US) | 2002-08-01 | — | — | WO | disclosed |
| EP-1226820-A1 | Use of bicyclic amino acids for preventing and treating visceral pain and gastrointestinal disorders | WARNER-LAMBERT COMPANY (US) | 2002-07-31 | — | — | EP | disclosed |
| EP-1226110-A1 | BICYCLIC AMINO ACIDS AS PHARMACEUTICAL AGENTS | WARNER-LAMBERT COMPANY (US) | 2002-07-31 | — | — | EP | disclosed |
| US-20020072533-A1 | Method of treating cartilage damage | SCHRIER DENIS (US) | 2002-06-13 | — | — | US | disclosed |
| EP-1202986-A1 | AMINE AND AMIDE DERIVATIVES AS LIGANDS FOR THE NEUROPEPTIDE Y Y5 RECEPTOR USEFUL IN THE TREATMENT OF OBESITY AND OTHER DISORDERS | Ortho-McNeil Pharmaceutical, Inc. (US) | 2002-05-08 | — | — | EP | disclosed |
| US-6380224-B1 | FOR THERAPY OF EATING DISORDERS, OBESITY, BULIMIA NERVOSA, DIABETES, MEMORY LOSS, EPILEPTIC SEIZURES, MIGRAINE, SLEEP DISTURBANCES, PAIN, SEXUAL/REPRODUCTIVE DISORDERS, DEPRESSION AND ANXIETY | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2002-04-30 | — | — | US | disclosed |
| EP-1199072-A2 | Method of treating cartilage damage | WARNER-LAMBERT COMPANY (US) | 2002-04-24 | — | — | EP | disclosed |
| EP-1194399-A2 | NOVEL AMINOINDANES | Prescient Neuropharma Inc. (CA) | 2002-04-10 | — | — | EP | disclosed |
| US-6300376-B1 | FOR THERAPY TO ACHIEVE SMOOTH MUSCLE RELAXING ACTIVITY AND/OR MAST CELL STABILIZING ACTIVITY AND/OR ANTI-INFLAMMATORY ACTIVITY | VENANTIUS LIMITED (IR) | 2001-10-09 | — | — | US | disclosed |
| US-6297399-B1 | HYPOTENSIVE AGENTS | VENANTIUS LIMITED (IE) | 2001-10-02 | — | — | US | disclosed |
| US-6288059-B1 | ANTIASTHMATIC, ANTIALLERGEN AGENTS; URINARY INCONTINENCE; NATURAL KILLER CELL RECEPTOR AND TACHYKININ ANTAGONISTS | SANKYO COMPANY, LIMITED (JP) | 2001-09-11 | — | — | US | disclosed |
| EP-0970957-B1 | Diaza-spiro[3,5] nonane derivatives | HOFFMANN LA ROCHE (CH) | 2001-08-16 | — | — | EP | disclosed |
| EP-1117397-A1 | GEOMETRICALLY RESTRICTED 2-INDOLINONE DERIVATIVES AS MODULATORS OF PROTEIN KINASE ACTIVITY | Sugen, Inc. (US) | 2001-07-25 | — | — | EP | disclosed |
| EP-0856514-B1 | 8-substituted-1,3,8-triazaspiro[4.5]decan-4-on derivatives | HOFFMANN LA ROCHE (CH) | 2001-06-13 | — | — | EP | disclosed |
| WO-2001040238-A1 | BRIDGED METALLOCENE COMPOUNDS AS OLEFIN-POLYMERIZATION CATALYSTS | POLIMERI EUROPA S.P.A. (IT) | 2001-06-07 | — | — | WO | disclosed |
| WO-2001028978-A1 | BICYCLIC AMINO ACIDS AS PHARMACEUTICAL AGENTS | WARNER-LAMBERT COMPANY (US) | 2001-04-26 | — | — | WO | disclosed |
| CN-1284070-A | Alicyclic acylated heterocyclic derivatives | SANKYO CO (JP) | 2001-02-14 | — | — | CN | disclosed |
| WO-2001009120-A1 | AMINE AND AMIDE DERIVATIVES AS LIGANDS FOR THE NEUROPEPTIDE Y Y5 RECEPTOR USEFUL IN THE TREATMENT OF OBESITY AND OTHER DISORDERS | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2001-02-08 | — | — | WO | disclosed |
| WO-2001002340-A2 | NOVEL AMINOINDANES | IGT PHARMA INC. (CA) | 2001-01-11 | — | — | WO | disclosed |
| EP-1048658-A1 | ALICYCLIC ACYLATED HETEROCYCLIC DERIVATIVES | Sankyo Company Limited (JP) | 2000-11-02 | — | — | EP | disclosed |
| EP-0745099-B1 | REACTOR BLEND POLYPROPYLENE AND PROCESS FOR THE PREPARATION THEREOF | MONTELL TECHNOLOGY COMPANY BV (NL) | 2000-09-13 | — | — | EP | disclosed |
| EP-1035095-A1 | Method for making 1,2-Dibromoindane | Ichikawa Gosei Chemical Co., Ltd. (JP) | 2000-09-13 | — | — | EP | disclosed |
| US-6113527-A | 3,3-BIS-HYDROXYMETHYL-7-(CIS-4-ISOPROPYL-CYCLOHEXYL)-1-PHENYL -1,7-DIAZA-SPIRO-(3.5)NONANE-2-ONE, FOR EXAMPLE; AGONISTS OF THE ORPHANIN FQ (OFQ) RECEPTOR; USEFUL IN THE TREATMENT OF PSYCHIATRIC, NEUROLOGICAL AND PHYSIOLOGICAL DISORDERS | HOFFMANN-LA ROCHE INC. (US) | 2000-09-05 | — | — | US | disclosed |
| US-6107431-A | CATALYTIC POLYMERIZATION OF POLYPROPYLENE THERMOPLASTIC ELASTOMER USING ALUMOXANE-METALLOCENE DERIVATIVE CATALYST | MONTELL TECHNOLOGY COMPANY BV (NL) | 2000-08-22 | — | — | US | disclosed |
| US-6071925-A | ANTIDEPRESSANTS, ANTICONVULSANTS OR ANTIANXIETY AGENTS, ALSO FOR TREATMENT OF MEMORY LOSS IN ALZHEIMER'S DISEASE | HOFFMANN-LA ROCHE INC. (US) | 2000-06-06 | — | — | US | disclosed |
| US-6071928-A | Spiro-piperidine derivatives and their use as therapeutic agents | MERCK SHARP & DOHME, LTD. (GB) | 2000-06-06 | — | — | US | disclosed |
| WO-2000012084-A1 | GEOMETRICALLY RESTRICTED 2-INDOLINONE DERIVATIVES AS MODULATORS OF PROTEIN KINASE ACTIVITY | SUGEN, INC. (US) | 2000-03-09 | — | — | WO | disclosed |
| EP-0970957-A1 | Diaza-spiro[3,5] nonane derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2000-01-12 | — | — | EP | disclosed |
| EP-0952978-A1 | METALLOCENES AND CATALYSTS FOR OLEFIN-POLYMERISATION | Montell Technology Company bv (NL) | 1999-11-03 | — | — | EP | disclosed |
| US-5968954-A | EXHIBIT SELECTIVE BINDING AFFINITY FOR 5-HYDROXYTRYPTAMINE RECEPTORS | ADIR ET COMPAGNIE (FR) | 1999-10-19 | — | — | US | disclosed |
| EP-0935608-A1 | CYTOTOXIC PEPTIDES | BIOMOLECULAR RESEARCH INSTITUTE LTD. (AU) | 1999-08-18 | — | — | EP | disclosed |
| US-5929089-A | ANTISEROTONINE AGENT | SYNTHELABO (FR) | 1999-07-27 | — | — | US | disclosed |
| CN-1218051-A | New 2,3-dioxide, indanol compounds, process for their preparation and pharmaceutical compositions containing them | ADIR (FR) | 1999-06-02 | — | — | CN | disclosed |
| WO-1999024446-A1 | METALLOCENES AND CATALYSTS FOR OLEFIN-POLYMERISATION | MONTELL TECHNOLOGY COMPANY B.V. (NL) | 1999-05-20 | — | — | WO | disclosed |
| US-5841000-A | CONTINUOUSLY HYDROLYZING 1,2-DIBROMOINDANE WITHOUT ISOLATING IT | ICHIKAWA GOSEI CHEMICAL CO., LTD. (JP) | 1998-11-24 | — | — | US | disclosed |
| EP-0873301-A1 | INDANE COMPOUNDS WITH SMOOTH MUSCLE RELAXING AND/OR MAST CELL STABILISING AND/OR ANTI-INFLAMMATORY ACTIVITY | Venantius Limited (IE) | 1998-10-28 | — | — | EP | disclosed |
| EP-0865419-A1 | INDANE DIMER COMPOUNDS AND THEIR PHARMACEUTICAL USE | Venantius Limited (IE) | 1998-09-23 | — | — | EP | disclosed |
| EP-0856514-A1 | 8-substituted-1,3,8-triazaspiro[4.5]decan-4-on derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1998-08-05 | — | — | EP | disclosed |
| US-5747621-A | CATALYTIC ADDITION POLYMERIZATION | MONTELL TECHNOLOGY COMPANY BV (NL) | 1998-05-05 | — | — | US | disclosed |
| WO-1998013377-A1 | CYTOTOXIC PEPTIDES | BIOMOLECULAR RESEARCH INSTITUTE LTD. (AU) | 1998-04-02 | — | — | WO | disclosed |
| US-5723473-A | Propenoic acid derivatives useful as fungicides | ZENECA LIMITED (GB) | 1998-03-03 | — | — | US | disclosed |
| US-5719280-A | REACTING AMINE SUBSTITUTED BENZOCYCLOALKANE WITH DIALKYLOXYACETALDEHYDE IN PRESENCE OF REDUCING AGENT OR CATALYTIC HYDROGENATION, TREATING WITH THIOCYANIC ACID | SYNTEX (U.S.A.) INC. (US) | 1998-02-17 | — | — | US | disclosed |
| EP-0816317-A1 | PROCESS FOR PRODUCING TRANS-2-BROMOINDAN-1-OL | ICHIKAWA GOSEI CHEMICAL CO., LTD. (JP) | 1998-01-07 | — | — | EP | disclosed |
| WO-1997020806-A1 | INDANE COMPOUNDS WITH SMOOTH MUSCLE RELAXING AND/OR MAST CELL STABILISING AND/OR ANTI-INFLAMMATORY ACTIVITY | VENANTIUS LIMITED (IE) | 1997-06-12 | — | — | WO | disclosed |
| WO-1997020802-A1 | INDANE DIMER COMPOUNDS AND THEIR PHARMACEUTICAL USE | VENANTIUS LIMITED (IE) | 1997-06-12 | — | — | WO | disclosed |
| EP-0757677-A1 | BENZOCYCLOALKYLAZOLETHIONE DERIVATIVES | SYNTEX (U.S.A.) INC. (US) | 1997-02-12 | — | — | EP | disclosed |
| EP-0745099-A1 | REACTOR BLEND POLYPROPYLENE, PROCESS FOR THE PREPARATION THEREOF AND PROCESS FOR PREPARING METALLOCENE LIGANDS | Montell Technology Company bv (NL) | 1996-12-04 | — | — | EP | disclosed |
| US-5538988-A | CARDIOVASCULAR DISORDERS AND DOPAMINE HYDROLASE ENZYME INHIBITORS | SYNTEX (U.S.A.) INC. | 1996-07-23 | — | — | US | disclosed |
| WO-1996020225-A2 | REACTOR BLEND POLYPROPYLENE, PROCESS FOR THE PREPARATION THEREOF AND PROCESS FOR PREPARING METALLOCENE LIGANDS | MONTELL TECHNOLOGY COMPANY B.V. (NL) | 1996-07-04 | — | — | WO | disclosed |
| WO-1995029165-A2 | BENZOCYCLOALKYLAZ0LETHIONE DERIVATIVES AS DOPAMIN BETA-HYDROXYLASE INHIBITORS | SYNTEX (U.S.A.) INC. (US) | 1995-11-02 | — | — | WO | disclosed |
| EP-0664795-A1 | PROPENOIC ACID DERIVATIVES USEFUL AS FUNGICIDES | ZENECA LIMITED (GB) | 1995-08-02 | — | — | EP | disclosed |
| US-5382497-A | Optical recording medium and process for recording thereupon | CANON KABUSHIKI KAISHA (JP) | 1995-01-17 | — | — | US | disclosed |
| US-5320930-A | Irradiating to form detectable pits; containing pyrylium, cyanine, merocyanine dyes, selenapyrylium and methine dyes | CANON KABUSHIKI KAISHA (JP) | 1994-06-14 | — | — | US | disclosed |
| WO-1994008968-A1 | PROPENOIC ACID DERIVATIVES USEFUL AS FUNGICIDES | ZENECA LIMITED (GB) | 1994-04-28 | — | — | WO | disclosed |
| US-5278026-A | Comprising photosensitive compounds | CANON KABUSHIKI KAISHA (JP) | 1994-01-11 | — | — | US | disclosed |
| US-5246814-A | Mehtine or pyrylium dye | CANON KABUSHIKI KAISHA (JP) | 1993-09-21 | — | — | US | disclosed |
| US-5194437-A | Substituted with oxygen containing heterocycle, central nervous system disorders, neuroendocrine disorders | ADIR ET COMPAGNIE (FR) | 1993-03-16 | — | — | US | disclosed |
| EP-0137333-B1 | SPIRO-TRICYCLICAROMATIC SUCCINIMIDE DERIVATIVES AS INHIBITORS OF ALDOSE REDUCTASE | ALCON LABORATORIES, INC. (US) | 1992-12-30 | — | — | EP | disclosed |
| US-5153211-A | Enzyme inhibitors | ALCON LABORATORIES, INC. (US) | 1992-10-06 | — | — | US | disclosed |
| CN-1016506-B | Preparation method of 1, 2-indane sulfonamide compound with antiarrhythmic drug activity | PFIZER LTD (GB) | 1992-05-06 | — | — | CN | disclosed |
| US-5079127-A | Methine Dyes | CANON KABUSHIKI KAISHA (JP) | 1992-01-07 | — | — | US | disclosed |
| US-5079128-A | Thin film containing a methine dye having at least two dimethylaminophenyl groups and a carbonium ion; laser writing; heat resistance | CANON KABUSHIKI KAISHA (JP) | 1992-01-07 | — | — | US | disclosed |
| US-5070100-A | COMPLICATIONS OF DIABETES | ALCON LABORATORIES, INC. (US) | 1991-12-03 | — | — | US | disclosed |
| CN-1038449-A | Antiarrhythmics | PFIZER LTD (GB) | 1990-01-03 | — | — | CN | disclosed |
| US-4864028-A | ANTIDIABETIC AGENTS | ALCON LABORATORIES, INC. (US) | 1989-09-05 | — | — | US | disclosed |
| US-4599347-A | ANTIULCER AGENTS | HOFFMANN-LA ROCHE INC. (US) | 1986-07-08 | — | — | US | disclosed |
| US-4554280-A | ANTISECRETORY AGENTS, ANTIULCER AGENTS | HOFFMANN-LA ROCHE INC. (US) | 1985-11-19 | — | — | US | disclosed |
| US-4540705-A | Antidepressant imidazolines and related compounds | STERLING DRUG INC. (US) | 1985-09-10 | — | — | US | disclosed |
| US-4537892-A | ANTIDIABETIC AGENTS | ALCON LABORATORIES, INC. (US) | 1985-08-27 | — | — | US | disclosed |
| US-4521607-A | HYPOTENSIVE | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1985-06-04 | — | — | US | disclosed |
| EP-0137333-A2 | Spiro-tricyclicaromatic succinimide derivatives as inhibitors of aldose reductase | ALCON LABORATORIES, INC. (US) | 1985-04-17 | — | — | EP | disclosed |
| EP-0125410-A2 | Imidazolines and related compounds and preparation thereof | STERLING DRUG INC. (US) | 1984-11-21 | — | — | EP | disclosed |
| US-4479007-A | Chroman-4-ones and process for preparing same | BAYER AKTIENGESELLSCHAFT (DE) | 1984-10-23 | — | — | US | disclosed |
| US-4435406-A | 2-PYRIDYL DERIVATIVES OF 1,3-DIOXOLO(4,5-F)BENZIMIDAZOLE RING COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 1984-03-06 | — | — | US | disclosed |
| US-4415741-A | REACTING O-HYDROXYACETOPHENONE AND CYCLOPENTANONE | BAYER AKTIENGESELLSCHAFT (DE) | 1983-11-15 | — | — | US | disclosed |
| US-4380672-A | Conversion of 2-phenyl propanal to 2-indanone | THE STANDARD OIL COMPANY (US) | 1983-04-19 | — | — | US | disclosed |
| US-4370323-A | 2-Cyanoaziridinyl-(1)-2-substituted-aziridinyl-(1)-methanes | BOEHRINGER MANNHEIM GMBH (DE) | 1983-01-25 | — | — | US | disclosed |
| EP-0035868-A1 | Bicyclic compounds, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1981-09-16 | — | — | EP | disclosed |
| US-4179569-A | ANALGESIC INTERMEDIATES | JANSSEN PHARMACEUTICA N.V. (BE) | 1979-12-18 | — | — | US | disclosed |
| US-3998834-A | ANALGESICS | JANSSEN PHARMACEUTICA N.V. (BE) | 1976-12-21 | — | — | US | disclosed |
| US-3998834-A | ANALGESICS | JANSSEN PHARMACEUTICA N.V. (BE) | 1976-12-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (50 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160159785-A1 | SUBSTITUTED-QUINOXALINE-TYPE PIPERIDINE COMPOUNDS AND THE USES THEREOF | P2RX4, P2RX5, P2RX3 | CYP1A2 950/4885CYP2A6 1358/4885MAOA 1006/4885 |
| US-20140031544-A1 | ARYL-AND HETEROARYLCARBONYL DERIVATIVES OF HEXAHYDROINDENOPYRIDINE AND OCTAHYDROBENZOQUINOLINE | HSD17B1, HSD3B1, HSD11B1 | CYP1A2 24/4885CYP2A6 111/4885MAOA 642/4885 |
| US-20180240988-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | OCIAD1, OCIAD2, OSBP | CYP1A2 1235/4885CYP2A6 3152/4885MAOA 874/4885 |
| US-20050187145-A1 | Template-fixed peptidommetics as inhibitors of serine proteases | PREP, CTRL, SERPINH1 | CYP1A2 3842/4885CYP2A6 2980/4885MAOA 1256/4885 |
| US-20080070919-A1 | BRIDGED ARYL PIPERAZINES DERIVATIVES USEFUL FOR THE TREATMENT OF CNS, GI-URINARY AND REPRODUCTIVE DISORDERS | HTR1A, HTR5A, TPH1 | CYP1A2 91/4885CYP2A6 268/4885MAOA 67/4885 |
| US-20180186780-A1 | METHODS TO TREAT LYMPHOPLASMACYTIC LYMPHOMA | IRAK1, IRAK4, IRAK2 | CYP1A2 3850/4885CYP2A6 3566/4885MAOA 4530/4885 |
| US-20110319423-A1 | NOVEL DOPAMINE D3 RECEPTOR LIGANDS AND PREPARATION AND MEDICAL USES OF THE SAME | DRD3, DRD2, SLC6A3 | CYP1A2 2068/4885CYP2A6 2037/4885MAOA 1285/4885 |
| US-20140249174-A1 | ARYL-AND HETEROARYLCARBONYL DERIVATIVES OF HEXAHYDROINDENOPYRIDINE AND OCTAHYDROBENZOQUINOLINE | HSD17B1, HSD3B1, HSD11B1 | CYP1A2 24/4885CYP2A6 111/4885MAOA 642/4885 |
| US-20140371446-A1 | PHOSPHINE LIGANDS FOR CATALYTIC REACTIONS | PHOSPHO1, PPIP5K2, ITPA | CYP1A2 2321/4885CYP2A6 1829/4885MAOA 1243/4885 |
| US-20180155320-A1 | 2-OXO-1,2-DIHYDROPYRIDINE-3-CARBOXAMIDE COMPOUNDS AND THEIR USE AS INHIBITORS OF PDK1 | PDK1, PDK2, PDK3 | CYP1A2 2240/4885CYP2A6 4069/4885MAOA 1492/4885 |
| US-20120157488-A1 | ARYL-AND HETEROARYLCARBONYL DERIVATIVES OF HEXAHYDROINDENOPYRIDINE AND OCTAHYDROBENZOQUINOLINE | HSD17B1, HSD3B1, HSD11B1 | CYP1A2 24/4885CYP2A6 111/4885MAOA 642/4885 |
| US-20100119475-A1 | NOVEL INHIBITORS OF GLUTAMINYL CYCLASE | GLS, GLS2, GLUL | CYP1A2 3261/4885CYP2A6 3958/4885MAOA 2405/4885 |
| US-20080176883-A1 | Antiinflammtory, antiproliferative, anticancer agents; (3-Hydroxy-pyrrolidin-1-yl)-(3-trifluoromethyl-7,8-dihydro-5H-[1,6]naphthyridin-6-yl)-methanone | MIF, CCL5, CCR2 | CYP1A2 834/4885CYP2A6 799/4885MAOA 3462/4885 |
| US-12358887-B2 | IKAROS Zinc Finger Family degraders and uses thereof | IKZF2, IKZF1, IKZF3 | CYP1A2 2296/4885CYP2A6 3022/4885MAOA 3027/4885 |
| US-20230271933-A1 | HETEROCYCLIC IMMUNOMODULATOR | IL2, ICOS, IL5 | CYP1A2 105/4885CYP2A6 214/4885MAOA 1040/4885 |
| US-20180079843-A1 | METALLOCENE COMPLEX WITH A HETEROATOM-CONTAINING PI-LIGAND AND PREPARATION METHOD THEREFOR, CATALYST SYSTEM CONTAINING THE SAME AND USE THEREOF | NR4A2, NR4A1, ORC3 | CYP1A2 766/4885CYP2A6 1009/4885MAOA 2253/4885 |
| US-12209092-B2 | Inhibitors of GLI1 as therapeutic agents | GLI1, GLI2, SHH | CYP1A2 4805/4885CYP2A6 4734/4885MAOA 4212/4885 |
| US-20220024941-A1 | Preparation Method for Amide Compounds and Use Thereof in Medical Field | EZH2, EZH1, IKZF2 | CYP1A2 2685/4885CYP2A6 2644/4885MAOA 2359/4885 |
| US-20230183218-A1 | CONDENSED SUBSTITUTED HYDROPYRROLES AS ANTAGONISTS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | CHRM3, CHRM2, CHRM4 | CYP1A2 2399/4885CYP2A6 1949/4885MAOA 773/4885 |
| US-20070203205-A1 | Diarylsulfones as 5-HT2A antagonists | HTR2A, HTR2B, HTR1A | CYP1A2 143/4885CYP2A6 201/4885MAOA 46/4885 |
| US-20080167378-A1 | Receptor Function Regulation Agent | GPR119, INSR, GPR88 | CYP1A2 3495/4885CYP2A6 2565/4885MAOA 3252/4885 |
| US-20130217876-A1 | PHOSPHINE LIGANDS FOR CATALYTIC REACTIONS | PHOSPHO1, PLCG2, PPIP5K2 | CYP1A2 3435/4885CYP2A6 3470/4885MAOA 2469/4885 |
| US-12030857-B2 | Glucose uptake inhibitors | SLC2A1, SLC2A4, SLC2A2 | CYP1A2 1359/4885CYP2A6 1387/4885MAOA 4607/4885 |
| US-20130281476-A1 | Modulators of Muscarinic Receptors | CHRM3, CHRM5, CHRM2 | CYP1A2 1140/4885CYP2A6 1510/4885MAOA 574/4885 |
| US-20030176504-A1 | Method of treating tinnitus | ADRA2A, ADRA1A, ADRA1D | CYP1A2 483/4885CYP2A6 907/4885MAOA 1248/4885 |
| US-20170002016-A1 | AZASPIRO DERIVATIVES AS TRPM8 ANTAGONISTS | TRPM8, TRPM7, TRPM5 | CYP1A2 2052/4885CYP2A6 1537/4885MAOA 2226/4885 |
| US-20220017541-A1 | INHIBITORS OF ARGINASE | ARG1, ARG2, ARGLU1 | CYP1A2 1519/4885CYP2A6 3230/4885MAOA 1017/4885 |
| US-20110218192-A1 | Inhibitors Of Beta-Secretase | BACE1, BACE2, APP | CYP1A2 2797/4885CYP2A6 2627/4885MAOA 799/4885 |
| US-20100216726-A1 | Substituted-Quinoxaline-Type Piperidine Compounds and the Uses Thereof | P2RX4, P2RX5, P2RX3 | CYP1A2 950/4885CYP2A6 1358/4885MAOA 1006/4885 |
| US-20180097187-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | OCIAD1, OCIAD2, OSBP | CYP1A2 1235/4885CYP2A6 3152/4885MAOA 874/4885 |
| US-20120122869-A1 | TRIZAOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | HSP90AB1, HSP90B1, CDC37 | CYP1A2 2619/4885CYP2A6 4308/4885MAOA 3983/4885 |
| US-20090186882-A1 | CGRP RECEPTOR ANTAGONISTS | CALCRL, CALCR, GRPR | CYP1A2 2407/4885CYP2A6 2988/4885MAOA 1128/4885 |
| US-20160324973-A1 | COMPOSITION COMPRISING A POLYMERIC REAGENT | CAT, LPO, GPX4 | CYP1A2 795/4885CYP2A6 1719/4885MAOA 221/4885 |
| US-20070161638-A1 | Compounds which potentiate glutamate receptor and uses thereof in medicine | GRM1, GRIN1, HCAR1 | CYP1A2 980/4885CYP2A6 891/4885MAOA 2163/4885 |
| US-11196010-B2 | Organic electroluminescent materials and devices | OCIAD1, OCIAD2, OSBP | CYP1A2 1170/4885CYP2A6 3357/4885MAOA 1140/4885 |
| US-20120258912-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR DELIVERING SUCH COMPOSITIONS | ABCG2, SI, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | CYP1A2 963/4885CYP2A6 233/4885MAOA 990/4885 |
| US-10662174-B2 | BTK inhibitor | BTK, SYK, LYN | CYP1A2 3859/4885CYP2A6 3840/4885MAOA 3393/4885 |
| US-20240150293-A1 | SPIROCYCLOHEXANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS ANTI-APOPTOTIC INHIBITORS | BCL2, BAX, BCL2A1 | CYP1A2 888/4885CYP2A6 787/4885MAOA 3890/4885 |
| US-20020072533-A1 | Method of treating cartilage damage | COL2A1, COL1A1, GABRB1 | CYP1A2 1403/4885CYP2A6 1974/4885MAOA 2672/4885 |
| US-20060052445-A1 | Diarylsulfones as 5-HT2A antagonists | HTR2A, HTR2B, HTR1A | CYP1A2 143/4885CYP2A6 201/4885MAOA 46/4885 |
| US-20070130702-A1 | Dyeing process using a specific compound containing active methylene and a compound chosen from a specific aldehyde, a specific ketone, a quinone and a diiminoisoindoline or 3-aminoisoindolone derivative | KRT18, NDUFB5, NDUFB7 | CYP1A2 398/4885CYP2A6 799/4885MAOA 467/4885 |
| US-20130225582-A1 | BIARYL-SPIROAMINOOXZAOLINE ANALOGUES AS ALPHA 2C ADRENERGIC RECEPTOR MODULATORS | ADRA2C, ADRB2, ADRA2A | CYP1A2 82/4885CYP2A6 429/4885MAOA 353/4885 |
| US-20130005707-A1 | AMINOTRIAZOLOPYRIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | MAP3K2, MAP3K1, MAP3K3 | CYP1A2 654/4885CYP2A6 2016/4885MAOA 2285/4885 |
| US-20110166133-A1 | FUSED NITROGEN CONTAINING HETEROCYCLES AND COMPOSITIONS THEREOF AS KINASE INHIBITORS | ALK, ROS1, FLT3 | CYP1A2 4660/4885CYP2A6 4785/4885MAOA 1885/4885 |
| US-20140045811-A1 | AMIDE, UREA OR SULFONE AMIDE LINKED BENZOTHIAZOLE INHIBITORS OF ENDOTHELIAL LIPASE | LIPG, LIPE, CEL | CYP1A2 1807/4885CYP2A6 2285/4885MAOA 867/4885 |
| US-20110053920-A1 | SUBSTITUTED BICYCLIC PYRIMIDINES | DPYD, P2RX5, P2RX7 | CYP1A2 450/4885CYP2A6 656/4885MAOA 227/4885 |
| US-20100190767-A1 | Compounds for the treatment of inflammatory diseases | MALT1, IL1B, RORC | CYP1A2 156/4885CYP2A6 96/4885MAOA 2973/4885 |
| US-20130331395-A1 | BRIDGED ARYL PIPERAZINES DERIVATIVES USEFUL FOR THE TREATMENT OF CNS, GI-URINARY AND REPRODUCTIVE DISORDERS | HTR1A, HTR5A, TPH1 | CYP1A2 91/4885CYP2A6 268/4885MAOA 67/4885 |
| US-20090170861-A1 | Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors | MAN2A1, GYS2, MANBA | CYP1A2 310/4885CYP2A6 691/4885MAOA 1426/4885 |
| US-20160263566-A1 | PHOSPHINE LIGANDS FOR CATALYTIC REACTIONS | PHOSPHO1, PLCG2, PPIP5K2 | CYP1A2 3435/4885CYP2A6 3470/4885MAOA 2469/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.